WO2000033065A1 - In vivo biosensor apparatus and method of use - Google Patents
In vivo biosensor apparatus and method of use Download PDFInfo
- Publication number
- WO2000033065A1 WO2000033065A1 PCT/US1999/028733 US9928733W WO0033065A1 WO 2000033065 A1 WO2000033065 A1 WO 2000033065A1 US 9928733 W US9928733 W US 9928733W WO 0033065 A1 WO0033065 A1 WO 0033065A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- implantable
- cells
- monolithic bioelectronic
- bioelectronic device
- implantable monolithic
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/1459—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters invasive, e.g. introduced into the body by a catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/005—Enzyme electrodes involving specific analytes or enzymes
- C12Q1/006—Enzyme electrodes involving specific analytes or enzymes for glucose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/12—Manufacturing methods specially adapted for producing sensors for in-vivo measurements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0031—Implanted circuitry
Definitions
- the invention generally relates to the field of implantable diagnostic devices (i.e. devices deployed within the body of an animal) for monitoring one or more target substances, analytes, or metabolites in the animal. More particularly, the invention provides implantable biosensor devices for monitoring and regulating the level of analytes in the tissues and circulatory system of a human.
- the apparatus comprises a biosensor that is utilized to monitor the level of blood glucose in a diabetic or hypoglycemic patient.
- the disclosed sensors may also be used to control or regulate the delivery of a drug or other pharmaceutical agent from an external or an implantable drug delivery system.
- the device may form part of an artificial pancreas to regulate insulin dosage in response to the level of glucose detected in situ.
- Biosensors are hybrid devices combining a biological component with an analytical measuring element.
- the biological component reacts and/or interacts with the analyte(s) of interest to produce a response measurable by an electronic, optical, or mechanical transducer.
- the most common configurations presently available utilize immobilized macromolecules such as enzymes or antibodies to form the biological component.
- analytes and immobilized macromolecules include: glucose and immobilized glucose oxidase (e.g., Wilkins et al, 1995); nitrate and immobilized nitrate reductase (Wu et al, 1997); hydrogen peroxide and 2.3-dichlorophenoxyacetic acid and immobilized horseradish peroxidase (Rubtsova et al. 1998); and aspartate and immobilized L-aspartase (Campanella et al, 1995).
- glucose and immobilized glucose oxidase e.g., Wilkins et al, 1995
- nitrate and immobilized nitrate reductase Wang et al, 1997
- hydrogen peroxide and 2.3-dichlorophenoxyacetic acid and immobilized horseradish peroxidase (Rubtsova et al. 1998); and aspartate and immobilized L-aspartase (Campanella e
- biosensors A further refinement for biosensors has been developed in recent years that utilizes intact living cells, such as a microorganism, or an eukaryotic cell or cell culture as an alternative to immobilized enzymes.
- Microbial cells are especially well suited for biosensor technologies; they are physically robust, capable of existing under extremely harsh and widely fluctuating environmental conditions, they possess an extensive repertoire of responses to their environment, and they can be genetically engineered to generate reporter systems that are highly sensitive to these environmental responses.
- Polynucleotide sequences that comprise specific promoter sequences are operably linked to a gene or a plurality of genes that encode the desired reporter enzyme(s) and then introduced into and maintained within the living cell.
- reporter genes When the target analyte is present, the reporter genes are expressed, generating the enzyme(s) responsible for the production of the measured signal.
- Commonly used reporter systems have utilized either the ⁇ - galactosidase (lacZ) or catechol-2,3-dioxygenase (xylE) enzymes (Kricka, 1993).
- lacZ ⁇ - galactosidase
- xylE catechol-2,3-dioxygenase
- a limitation of these systems has been that following exposure to the target substance(s), the cells must be destructively lysed and the enzyme(s) isolated. This lysis is then followed by the addition of one or more secondary metabolites to yield a colorimetric signal that is proportional to the concentration of enzyme(s) in solution, providing a means to quantify the concentration of the original target substance.
- the present invention overcomes these and other inherent limitations in the prior art by providing implantable apparatus and methods for detecting and quantitating particular analytes in the body of an animal.
- the invention provides devices for the in vivo detection and quantitation of metabolites, drugs, hormones, toxins, or microorganisms such as viruses in a human or animal.
- the invention provides a BBIC device useful for the detection of glucose in a human. Such devices provide for the first time an accurate on-line detector for glucose monitoring, and offer the ability to control the administration of pharmaceutical agents via an external or implantable drug delivery system. Also disclosed are BBIC devices for detecting the concentration of signature molecules (i.e.
- the biosensor devices find utility in both initial and remission monitoring, on-line measurement of the effectiveness of chemotherapy, and stimulation/activity of the immune system.
- an implantable monolithic bioelectronic device for detecting an analyte within the body of an animal.
- this device comprises a bioreporter that is operably positioned above a substrate that is on an integrated circuit.
- the bioreporter is capable of metabolizing the target analyte and emits light consequent to this metabolism when in contact with the analyte.
- the device further comprises a sensor closely positioned to the integrated circuit that detects the emitted light and generates an electrical signal in proportion to the amount of light generated by the bioreporter.
- the entire implantable device is contained within a biocompatible container that is implanted within the body of the animal in which the anaiyte detection is desired.
- the biocompatible container may be comprised of silicon nitride, silicon oxide, or a suitable polymeric matrix, with exemplary matrices such as polyvinyl alcohol, poly-L- lysine, and alginate being particularly preferred.
- the polymeric matrix may also further comprise a microporous, mesh-reinforced or a filter-supported hydrogel.
- the bioreporter preferably comprises a plurality of eukaryotic or prokaryotic cells that produce a bioluminescent reporter polypeptide in response to the presence of the target analyte.
- Prokaryotic cells such as one or more strains of bacteria, and eukaryotic cells such as mammalian cells are particularly preferred.
- Exemplary mammalian cells are human cells such as islet ⁇ -cells, immortal stem cells, or hepatic cells, with immortal stem cells being particularly preferred.
- These cells preferably comprise one or more nucleic acid segments that encode a luciferase polypeptide or a green fluorescent protein that is produced by the cells in response to the presence of the analyte.
- the nucleic acid segment encodes an Aqueorea Victoria, Renilla reniformis, or a humanized green fluorescent protein, or more preferably, a bacterial Lux polypeptide, such as the LuxA, LuxB, LuxC, LuxD, or LuxE polypeptide, or the LuxAB or LuxCDE fused polypeptides described herein.
- Exemplary bacterial lux gene sequences that may be employed to prepare the genetic constructs include the Vibrio fischerii or more preferably, the Xenorhabdus luminescens luxA, luxB, luxC. luxD, luxE, luxAB, or luxCDE genes.
- Exemplary lux gene sequences that may be employed for preparation of the genetic constructs as described herein include the gene sequences disclosed in SEQ ID NO:l .
- Exemplary Lux polypeptide sequences are disclosed in SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6.
- the Lux polypeptides preferably comprise at least a 10 contiguous amino acid sequence from one or more of the polypeptide sequences disclosed in SEQ ID NO:2 through SEQ ID NO:6. More preferably the Lux polypeptides comprise at least a 15 contiguous amino acid sequence from one or more of the polypeptide sequences disclosed in SEQ ID NO:2 through SEQ ID NO:6, and more preferably still, comprise at least a 20 contiguous amino acid sequence from one or more of the polypeptide sequences disclosed in SEQ ID NO:2 through SEQ ID NO:6.
- polypeptides are preferably encoded by a nucleic acid sequence that comprises at least 20. at least 25, at least 30, at least 35. at least 40, or at least 45 or more contiguous nucleotides from SEQ ID NO: 1.
- the expression of the Lux-encoding nucleic acid segments is preferably regulated by a nucleic acid regulatory sequence operably linked to the Lux-encoding segment.
- this regulatory sequence comprises a cw-acting element that is responsive to the presence of the target analyte.
- exemplary -acting response elements are selected from the group consisting of an S14 gene sequence, a hepatic L-pyruvate kinase gene sequence, a hepatic 6-phosphofructo-2-kinase gene sequence, a ⁇ -islets insulin gene sequence, a mesangial transforming growth factor- ⁇ gene sequence, and an acetyl- coenzyme-A carboxylase gene sequence.
- the cw-acting response element comprises a contiguous nucleotide sequence from a ⁇ -islets insulin gene sequence or a hepatic L- pyruvate kinase gene sequence. Expression of the nucleic acid sequence is preferably regulated by a promoter sequence such as the one derived from an L-pyruvate kinase- encoding gene described herein.
- the device may further comprise a wireless transmitter, an antenna, and a source of nutrients capable of sustaining the bioreporter cells.
- the biocompatible container enclosing the bioreporter may further comprise a membrane that is permeable to the analyte but not to the bioreporter cells themselves. Such a semi-permeable membrane permits analytes to flow freely from the bodily fluid into the detector device, but restricts the migration of bioreporter cells from the device into the surrounding tissues or circulatory system of the body in which the device is implanted.
- the integrated circuit is a complementary metal oxide semiconductor (CMOS) integrated circuit.
- the integrated circuit may comprise one or more phototransducer. that themselves may be comprised of one or more photodiodes.
- the integrated circuit may also further comprise a photodiode, a current-to- frequency converter, a digital counter, and/or a transmitter that is capable of transmitting either digital or analoa data.
- the invention also provides an implantable controlled drug delivery system that comprises both the BBIC device and an implantable drug delivery pump that is capable of being operably controlled by the BBIC and that is capable of delivering the drug to the body of the animal in response to controls by the device.
- the invention also concerns a method of providing a controlled supply of a drug to a patient in need thereof. The method generally involves implanting within the body of the patient the controlled drug delivery system
- the invention also provides a method of determining the amount of a drug required by a patient in need thereof, such as in the case of giving a diabetic patient an appropriate amount of insulin.
- the method generally involves implanting within the body of the diabetic patient one or more BBIC devices that are responsive to either glucose, glucagons, insulin, or another glucose metabolite, and determining the amount of insulin required by the patient based upon the levels of the analyte detected in the body fluids by the device.
- the appropriate control signal can be sent to the drug delivery system and more insulin is injected into the body.
- the appropriate control signal can be sent to the drug delivery system and less insulin can be administered.
- Such "real-time" monitoring of glucose in the body of the animal permits for controlled release of insulin throughout the day, and obviates the need for daily or more frequent injections of insulin that may either be too much or too little for the particular time of administration. This affords a more cost-effective administration of the drug, and also provides a more stable dosing of the insulin to the patient on an "as needed" basis.
- kits for the detection of an analyte
- kits generally will include one or more of the disclosed BBIC devices in combination with appropriate instructions for using the detection device.
- kits may also routinely contain one or more standardized reference solutions for calibrating the device, and may also include suitable storage or nutrient medium for sustaining the bioreporter cells either during storage or during use once implanted within the body of the animal.
- suitable storage or nutrient medium for sustaining the bioreporter cells either during storage or during use once implanted within the body of the animal.
- such kits will also generally include one or more controlled delivery systems for administration of the drug to the body of the animal.
- the invention also provides a method of regulating the blood glucose level of an animal in need thereof.
- This method generally comprises monitoring the level of glucose in the bloodstream or inerstitial fluid of the patient using the BBIC device, and administering to the patient an effective amount of an insulin composition sufficient to regulate the blood glucose level.
- This new type of bioluminescence-based bioreporter is capable of monitoring target substances without the disadvantageous requirement that cells be destroyed to produce the measurable signal. This allows for monitoring to occur continuously, on-line and in real-time (Simpson et al, 1998a, 1998b). These cells rely on luciferase genes (designated lux in prokaryotes and luc in eukaryotes) for the reporter enzyme system. U.
- BBIC bioluminescence bioreporter integrated circuit
- the implantable monolithic bioelectronic device of the present invention generally comprises a substrate, a bioreporter capable of responding to a particular substance by the emission of light, a container affixed to the substrate capable of holding the bioreporter, an integrated circuit on the substrate including a phototransducer operative to generate an electrical signal in response to the light wherein the signal indicates the concentration of the substance: and a biocompatible housing that is capable of being implanted within the body of an animal, with that portion of the housing covering the bioreporter container comprising a semi-permeable membrane that permits passage of the analyte from the body of the animal to contact the biosensor, but restricts the bioreporter molecules from diffusing into the body of the animal that contains the implanted device.
- the bioreporter may be in solution, that is a cell suspension, and entrapped in the container by the semi- permeable membrane, or alternatively the bioreporter may be encapsulated in a selectively permeable polymer matrix that is capable of allowing the selected substance in solution reach the bioreporter.
- the matrix is optically clear.
- the apparatus may further comprise a layer of bioresistant/biocompatible material between the substrate and the container, such a layer of silicon nitride.
- the integrated circuit is preferably a CMOS integrated circuit, and the phototransducer is preferably a photodiode.
- the integrated circuit may also include a current to frequency converter and/or a digital counter. Additionally, the integrated circuit may also include one or more transmitters.
- Such transmitters may be wireless, or conventionally wired.
- the apparatus also includes a drug delivery device capable of receiving transmissions from the transmitter.
- a further embodiment of the invention is an implantable apparatus for detecting a selected substance in solution, which comprises an integrated circuit including a phototransducer adapted to input an electrical signal into the circuit in response to light, a bioreporter capable of responding to selected substance in solution by emitting light, the reporter adapted to contact the substance; and a transparent, biocompatible. and bioresistant separator positioned between the phototransducer and the bioreporter to enable light emitted from the bioreporter to strike the phototransducer.
- the selected substance is glucose.
- the bioreporter may be a mammalian cell that contains a nucleotide sequence that encodes one or more luminescent reporter molecules.
- a nucelotide sequence may comprise one or more lux genes.
- the lux genes comprise both luxCDE genes and fused luxAB genes.
- these lux genes are derived from Xenorhabdus luminescens.
- the lux genes may be regulated by a nucleic acid sequence comprising one or more cw-acting glucose response elements.
- the glucose response element may be derived from the ⁇ -islets or hepatic L-pyruvate kinase gene.
- the p.LPK.Luc FF plasmid is used to provide one or more glucose response elements and the L-pyruvate kinase promoter to drive the expression of one or more lux genes.
- the cells constituting the bioreporter may be in suspension, entrapped in place on the IC by a semi-permeable membrane.
- the cells constituting the bioreporter may be encapsulated in a polymer matrix affixed to IC. Such a matrix may be permeable to the selected substance in solution.
- a further embodiment of the invention concerns an implantable monolithic bioelectronic device for detecting a selected substance in body fluid.
- This device generally comprises a biocompatible housing; a bioreporter capable of responding to a selected substance by emitting; and, a sensor capable of generating an electrical signal in response to the reception of the emitted light.
- a device may also include a transparent, bioresistant and biocompatible separator positioned between the bioreporter and the sensor and a semi-permeable membrane positioned in the biocompatible housing so that the selected substance can access the bioreporter.
- kits may comprise, in suitable container means, one or more bioreporters and an integrated circuit including a phototransducer. Kits may further comprise a drug delivery device.
- FIG. 1 shows a perspective view of one illustrative embodiment of the invention.
- FIG. 2 shows a side view of an illustrative embodiment of the present invention.
- FIG. 3 shows a block diagram of an illustrative embodiment of the integrated circuit.
- FIG. 4A shows a high-quality photodetector that can be made using a standard N- well CMOS process.
- FIG. 4B shows two photodetector structures fabricated in a silicon-on-insulator CMOS process: on the left, a lateral PIN detector; on the right, a device similar to left except that the junction is formed with a Schottky junction.
- FIG. 5A shows a simple photodiode consisting of a P-diffusion layer, an N-well, and a P-substrate.
- FIG. 5B shows a circuit using a large area photodiode for efficient light collection, and a small-area diode in a feedback loop to supply the forward bias current that cancels out the photocurrent.
- FIG. 5C shows a circuit using correlated double sampling (CDS) to minimize the effects of low frequency (flicker) amplifier noise as well as time or temperature dependent variations in the amplifier offset voltage.
- CDS correlated double sampling
- FIG. 6 shows the current-to-frequency converter architecture of the apparatus.
- FIG. 7 shows a prototype BBIC biosensor.
- FIG. 8 shows a minimum detectable concentration of toluene as a function of integration time for the prototype BBIC employing the bioreporter Pseudomonas putida
- FIG. 9 shows the schematic representation of a peritoneal glucose biosensor and insulin pump.
- FIG. 10A shows a schematic representation of an implantable biosensor containing two separate photodetectors with the bioreporters responding to either an increase or decrease in glucose concentrations.
- FIG. 10B shows a side view of biosensor showing silastic covering.
- FIG. 10C shows a schematic representaion of the utilization of a selectably permeable membrane to protect bioreporters from the immune response.
- the Iuciferase system has been adapted for use in biosensors in vivo.
- the lux system consists of a Iuciferase composed of two subunits coded for by the genes luxA and luxB that oxidize a long chain fatty aldehyde to the corresponding fatty acid resulting in a blue-green light emission at an approximate wavelength of 490 nm
- the system also contains a multienzyme fatty acid reductase consisting of three proteins, a reductase encoded by luxC. a transferase encoded by luxD, and a synthetase encoded by luxE that convert and recycle the fatty acid to the aldehyde substrate.
- the genes are contained on a single operon, allowing for the cloning of the complete lux gene cassette downstream from user-specific promoters for the utilization of bioluminescence to monitor gene expression.
- bioluminescent bioreporters consist of Gram-negative organisms engineered to detect and monitor critically important chemical and environmental stressors (Ramanathan et al, 1997, Steinberg et al, 1995). Luciferase fusions in Gram-positive bacteria, as well as in yeast cell lines, are also being successfully performed (Andrew and Roberts, 1993. Srikantha et al, 1996). Eukaryotic luciferase genes cloned into bacterial reporters include the firefly luciferase (luc) producing light near 560 nm and the click beetle luciferase (lucOR) emitting light near 595 nm (Cebolla et al, 1995. Hastings, 1996).
- luc firefly luciferase
- lucOR click beetle luciferase
- Eukaryotic bioreporters have been designed to monitor glucose concentrations in rat islet ⁇ -cells (Kennedy et al, 1997), steroid activity in HeLa cells (Gagne et al. , 1994), ultraviolet light effects in mouse fibroblast cells (Filatov et al, 1996), toxicity effects in human liver cancer cells
- Green fluorescent protein is also routinely used as a reporter system, with the significant advantage that cells do not require destructive assay techniques to produce colorimetric signals (Hanakam et al, 1996; Grygorczyk et al, 1996; Siegel and Isacoff, 1997; Biondi et al, 1998). However, a substrate must be added to the GFP constructs to first initiate the light response (Prasher, 1995).
- Humanized GFP cDNA has been developed which is specifically adapted for high-level expression in mammalian cells, especially those of human origin (Zolotukhin 1996). Humanized GFP can be efficiently inserted into mammalian cells using viral vectors (Levy et al, 1996; Gram ei al, 1998).
- Detection of the bioluminescent signal from the reporter organisms is achieved through the use of optical transducers, including photomultiplier tubes, photodiodes, microchannel plates, photographic films, and charge-coupled devices. Light is collected and transferred to the transducer through lenses, fiber optic cables, or liquid light guides.
- optical transducers including photomultiplier tubes, photodiodes, microchannel plates, photographic films, and charge-coupled devices.
- Light is collected and transferred to the transducer through lenses, fiber optic cables, or liquid light guides.
- applications requiring small volumes, remote detection, or multiple parallel sensing necessitate a new type of instrumentation that is small and portable, yet maintains a high degree of sensitivity.
- the present invention describes an implantable BBIC that detects selected substances.
- the bioreporter is a genetically engineered cell line in which the nucleic acid sequence contains a cw-activating response element that is responsive to the selected substance.
- the selected substance is glucose.
- Exposure of the bioreporter to the selected substances causes the response element to up-regulate a nucleic acid sequence that encodes one or more polypeptides that generate a luminescent response.
- the luminescent response is generated by a prokaryotic lux system.
- the function of the IC portion of the BBIC is to detect, filter, amplify, digitize, and report the bioluminescent signal.
- the IC serves as a complete laboratory instrument-on-a-chip: a microluminometer.
- Silicon-based ICs can detect optical signals in the near ultraviolet, visible, and near infrared regions using the PN junctions normally used to form transistors (Simpson et al, 1999a). Using an n-well/p-substrate photodiode in a 0.5- ⁇ m bulk CMOS IC process, an -66% quantum efficiency has been measured at the 490-nm bioluminescent wavelength
- FIG. 6 shows the prototype BBIC (including the bioreporter enclosure) as used in the characterization studies
- a naphthalene-sensitive BBIC was produced using the microluminometer described above and the bioreporter P. fluorescens 5RL. Using the same experimental procedure described above, this BBIC was exposed to naphthalene vapor with a concentration of approximately 10 ppm. A signal of 240 counts/minute was recorded.
- the substrate is generated by a fatty acid reductase complex coded for by the luxCDE genes.
- This enzyme complex reduces short chain fatty acids to the corresponding aldehyde.
- the luciferase then oxidizes the aldehyde to the corresponding fatty acid.
- the preferred fatty acid for this reaction is myristic acid, which is present in eukaryotic organisms (Rudnick et al, 1993). Myristic acid is usually involved in the myristoylation of the amino terminus that is associated with membrane attachment (Borgese et al, 1996, Brand et al, 1996).
- the bioreporter for glucose monitoring will be a mammalian bioluminescent reporter cell line that has been genetically engineered to express luminescence in response to glucose concentrations on a continuous basis, without the need for cell destruction and exogenous substrate addition.
- Current methodologies using mammalian bioluminescent reporter cells require cell lysis and addition of an exogenous substrate to generate a measurable response. Consequently, these cells cannot serve as continuous on-line monitoring devices.
- this new cell line is constructed with a bioluminescent reporter utilizing the luxAB and luxCDE genes from X. luminescens incorporated into a plasmid-based system designated p.LPK.LuCpp which contains a eukaryotic luc gene able to respond to glucose concentrations.
- the bioreporters may be entrapped in a container behind a semi-permeable membrane that keeps them in place over the IC photodetector.
- the bioreporter may be encased in a polymer matrix.
- the BBIC is enclosed in a biocompatible housing with a semi-permeable membrane covering the bioreporter region. This membrane allows glucose to pass to the bioreporters, yet stops the passage of larger molecules that could interfere with the glucose measurement.
- the glucose reaches the bioreporter, it is metabolized and the cells emit visible light. The IC detects this light, amplifies and filters this signal, and then reports this measurement.
- FIG. 1 shows a perspective view of the present invention.
- Glucose 10 that is being detected enters the BBIC 11 through the semi-permeable membrane 12 that covers the bioreporter.
- FIG 2 shows a side view of the present invention.
- the BBIC is enclosed in a biocompatible housing 20 with a semi-permeable membrane 21 covering the bioreporter held in a container 22.
- the cells constituting the bioreporter may be in suspension or encapsulated in a polymer matrix.
- the bioreporter is separated from a photodetector 23 by a protective coating 24.
- a single substance 25 contains the photodetector as well as additional circuits 26 that process and transmits the signal.
- FIG. 3 shows a block diagram of one embodiment of the integrated circuit ("IC").
- the photodetector is a photodiode 33 connected to a current to frequency converter 30.
- the photodiode responds to light by sinking a current.
- the current is converted to a series of pulses that are accumulated in a digital counter 31.
- the number of counts in the counter in a fixed amount of time is directly proportional to the amount of light collected by the photodiode, which is directly proportional to the concentration of glucose.
- Digital processing circuitry in the digital counter would determine the appropriate next step for an insulin pump based on the measured glucose levels.
- the measured concentration or next instruction for the insulin pump could be reported via the wireless transmitter 32. All these circuits (photodiode, signal processing, and wireless transmission) can be fabricated on one IC.
- FIG. 4 shows the bioreporter being supplied with water and nutrients.
- a fluid and nutrient reservoir 141 is connected to a microfluidic pump 142 so that nutrient and fluid 144 may flow through the polymer matrix 143 enclosing the bioreporter.
- Each of these components can be constructed on a single substrate 140.
- FIG. 5A shows a high-quality photodetector made using a standard N-well CMOS process.
- the photodetector consists of two reverse biased diodes in parallel.
- the top diode is formed between the P+ active layer 45 and the N-well 46, and the bottom diode is formed between the N-well 46 and the P-substrate 47.
- the top diode has good short wavelength light sensitivity (400 - 550 nm), while the bottom diode provides good long wavelength sensitivity (500 - 1100 nm).
- the complete diode is sensitive over the range from 400 to 1 100 nm.
- FIG. 10A, FIG. 10B, and FIG. 10C show schematic representations of an implantable biosensor containing two separate photodetectors with the bioreporters responding to either an increase or decrease in glucose concentrations.
- FIG. 10B shows a side view of biosensor showing silastic covering.
- FIG. 10C shows a schematic representaion of the utilization of a selectably permeable membrane to protect bioreporters from the immune response.
- the first element in the micro-luminometer signal processing chain is the photodetector.
- the key requirements of the photodetector are: • Sensitivity to wavelength of light emitted by the bioluminescent or chemiluminescent compound under test; • Low background signal (i.e. leakage current) due to parasitic reverse biased diodes;
- the photodetector is fabricated in a standard N-well CMOS process. Shown in FIG. 5A, this detector is formed by connecting the PN junction between the PMOS active region and the N-well in parallel with the PN junction between the N-well and the P-type substrate. The resulting detector is sensitive to light between approximately 400 nm and approximately 1100 nm, a range that encompasses the 450 to 600 nm emission range of most commonly used bioluminescent and chemiluminescent compounds or organisms. In order to meet the requirement that the device have a low background signal, the device is operated with a zero bias, setting the operating voltage of the diode equal to the substrate voltage.
- the photodiode coating may be formed with a deposited silicon nitride layer or other material compatible with semiconductor processing techniques.
- the detector is fabricated in a silicon-on- insulator (SOI) CMOS process.
- SOI silicon-on- insulator
- the internal leakage current in an SOI process is two to three orders of magnitude lower than in standard CMOS due to the presence of a buried oxide insulating layer between the active layer and the substrate.
- Two photodetector structures are envisioned in the SOI process.
- the first structure shown on the left of FIG. 5B, consists of a lateral PIN detector where the P-layer is formed by the P+ contact layer, the I (intrinsic) region is formed by the lightly doped active layer, and the N region is formed by the N+ contact layer of the SOI CMOS process.
- the spectral sensitivity of this lateral detector is set by the thickness of the active layer, which may be tuned for specific bioluminescent and chemiluminescent compounds.
- the second structure shown on the right side of FIG. 3B. is similar to the first except that the junction is formed with a Schottky junction between a deposited cobalt suicide (CoSi 2 ) or other appropriate material layer and the lightly doped active layer.
- a deposited cobalt suicide CoSi 2
- the low noise electronics are the second element in the micro-luminometer signal processing chain.
- the requirements for the low noise electronics are:
- FIG. 6A schematically shows the first approach to the detection of very small signals.
- This device uses a P-diffusion/N-well photodiode. a structure compatible with standard CMOS IC processes, in the open circuit mode with a read-out amplifier (fabricated on the same IC with the photodiode).
- the luminescent signal generates electron-hole pairs in the P-diffusion and the N-well.
- the photo-generated electrons in the P-diffusion are injected into the N-well, while the photo-generated holes in the N-well are injected into the P-diffusion.
- the N-well is tied to ground potential so that no charge builds up in this region.
- the P-diffusion is only attached to the input impedance of a CMOS amplifier (which approaches infinity at low frequencies), a positive charge collects in this region.
- the voltage on the P-diffusion node begins to rise.
- the P-diffusion N-well photodiode becomes forward biased, thereby producing a current in a direction opposite to the photo- generated current.
- the system reaches steady state when the voltage on the P-diffusion node creates a forward bias current exactly equal in magnitude (but opposite in polarity) to the photocurrent. If this PN junction has no deviations from the ideal diode equation, then the output voltage is given by the following equation:
- V u V, ⁇ rx(I p / (A f) + 1), (Eq. 1)
- V is the thermal voltage (approximately 26 mV at room temperature)
- I p is the photo-current
- A is the cross-sectional area of this PN junction
- f is the reverse saturation current for a PN junction with unit cross- sectional area.
- I s depends greatly on the IC process and material parameters.
- V ou , V, ln((/ p + I g - I r ) I (A I,) + 1).
- This output voltage is a function of parameters that are generally beyond the inventors' control. However, the inventors do have control over the junction area. A. Unfortunately, to make the inventors' output signal larger, the inventors want a small A, while the inventors want a large A for a high quantum efficiency (QE). __
- FIG. 6B shows a second microluminometer embodiment that satisfies both of these needs.
- This circuit uses a large area photodiode for efficient light collection, but uses a small-area diode in a feedback loop to supply the forward bias current that cancels out the photocurrent.
- the amplifier and feedback diodes are fabricated on the same IC as the photodiode. For this circuit:
- V ml 3 V, ln((J,+ I g - I r ) I (A ⁇ + 1), (Eq. 3)
- a ⁇ is the small cross-sectional area of the feedback diode. More than one diode is used in the feedback path to make the output signal large compared to the DC offset of any subsequent amplifier stages. This technique allows efficient collection of the light with a large-area photodiode, yet produces a large output voltage because of the small- area diodes in the feedback path.
- the principal advantages of the second micro-luminometer embodiment shown in FIG. 6B include: • The SNR is totally determined by the photodiode; noise from the small diode and amplifier are negligible;
- Diodes can be added in the feedback path until the signal level at the output of the amplifier is significant compared to offset voltages (and offset voltage drift) of subsequent stages; • This method is completely compatible with standard CMOS processes with no additional masks, materials, or fabrication steps;
- This detection scheme can be fabricated on the same IC with analog and digital signal processing circuits and RF communication circuits; and,
- a third microluminometer implementation shown in FIG. 6C uses correlated double sampling (CDS) to minimize the effects of low frequency (flicker) amplifier noise as well as time or temperature dependent variations in the amplifier offset voltage.
- CDS correlated double sampling
- a photodiode with capacitance C d and noise power spectral density S is connected to an integrating preamplifier with feedback capacitance C f and input noise power spectral density S v through a set of switches that are controlled by the logical level of a flip-flop output.
- the switches When the flip-flop output is low, the switches are positioned so that the photocurrent flows out of the preamplifier, causing the output voltage of the integrator to increase.
- the low-pass filtered integrator output voltage exceeds a threshold, V HI , the upper comparator "fires” setting the flip-flop and causing its output to go high.
- the detector switches change positions, causing current to flow into the integrating amplifier, which in turn causes the amplifier output voltage to decrease.
- the integrator output goes below a second threshold, V w , the lower comparator "fires” resetting the flip-flop and causing the output to go low again. The process repeats itself as long as a photocurrent is present.
- V HI and V L0 are the threshold voltages of the comparators and I p is the diode photocurrent.
- S is the input noise current power spectral density associated primarily with the photodiode, and
- the noise voltage S of the preamplifier is determined by its design and has units of V 2 /Hz.
- the switches perform a correlated double sampling function that attenuates the noise that appears below the switching frequency of the output pulse string.
- the transfer function of a correlated double sampling circuit is approximated to first order by the equation:
- the error in measuring ⁇ t may be reduced by collecting many output pulses and obtaining an average period.
- the error in the measured average pulse period improves proportionately to the square root of the number of pulses collected, such that
- the accuracy of the measured photocurrent may be improved without limit by acquiring data for increasing periods of time.
- the communication method is an on-chip wireless communication system that reports the level of the photocurrent to computing circuitry contained within in vivo drug delivery system or an external receiver. In a closed-loop system, this computing circuitry would determine the amount of drug to be delivered by the in vivo drug delivery system. If an external receiver were used, the data from the BBIC along with the user inputs would be used to determine the amount of drug to be administered.
- the external receiver may include wireless transmission circuitry for communication with the in vivo drug delivery system or the drugs may be administered manually.
- Other methods of communicating BBIC data include; • Generation of a DC voltage level proportional to the photocurrent with a hardwire connection to an in vivo drug delivery system;
- On-chip implementation of an analog to digital converter that reports a numerical value proportional to the photocurrent with a hardwire connection to an in vivo drug delivery system
- On-chip implementation of a serial or parallel communications port that reports a number proportional to the photocurrent with a hardwire connection to an in vivo drug delivery system
- Wireless communication in vivo may be limited by signal attenuation by body fluids, tissues, and health-related limits on RF signal levels. This may require the BBIC and in vivo drug delivery system to be closely spaced, which may not be the optimum configuration for all cases. In such cases, the BBIC could communicate to an external receiver located ex vivo but closer to the BBIC. This receiver could be connected (hardwired or wirelessly) to a transmitter located ex vivo but closer to the in vivo drug delivery system.
- the BBIC is enclosed in a biocompatible housing with a semi-permeable membrane covering the bioreporter region.
- biocompatible coverings for implants and prosthetic devices so as to minimize capsule formation and physiological rejection has been an area of extensive investigation.
- U. S. Patent 5,370,684 and U. S. Patent 5,387,247 describe the application of a thin biocompatible carbon film to prosthetic devices.
- a biocompatible implant material comprising a three-dimensionally woven or knitted fabric of organic fibers is disclosed in U. S. Patent 5.711,960, specifically inlcuded nerein in its entirety.
- Other coverings for implants constructed to present a biocompatible surface to the body are described in U. S. Patent 5,653,755, U. S. Patent 5,779,734, and U.
- a semi-permeable membrane comprises that part of the BBIC housing that covers the bioreporter and entraps them on the integrated circuit. This membrane allows the selected substance, such as glucose, to pass to the bioreporter, yet prevents the passage of larger molecules. Membranes designed for use with glucose-oxidase based biosensors may also used in the preferred embodiments of the present invention.
- Membranes investigated and designed for use with glucose-oxidase based biosensors include, but are not limited to: polytetrafluoroethylene membranes (Vaidaya and Wilkins, 1993); perfluorinated ionomer membranes (Moussy et al, 1994); charged and uncharged polycarbonate membranes (Vadiya and Wilkins 1994); and cellulose acetate membranes (Wang and Yuan, 1995; Steinberg et al, 1988).
- other membranes have been developed for the use transplantation of islets or other cells bioengineered to produce insulin. The membranes must be permeable to glucose and other metabolites while exclude elements of the host immune system.
- Such membranes may be adapted for use with the present invention and include, but are not limited to: asymmetric poly(vinyl alcohol) membranes (Young et al, 1996); poly(L-lysine) membranes (Tziampazis and Sambanis, 1995); ployurethane (Zondervan et al, 1992); nucleopore membranes (Ohgawara et al, 1998) ; and agarose gel (Taniguchi et al, 1997).
- Biocompatible semi- permeable membranes for encapsulation of cells to form an artificial organ are described in U. S. Patent 5,795,790 and U. S. Patent 5,620,883 (each specifically incorporated herein by reference in its entirety).
- a biocompatible semi-permeable segmented block polyurethane copolymer membrane and its use for permeating molecules of predetermined molecular weight range are disclosed in U.S. Patent No. 5,428,123, (specifcally incorporated herein by reference in its entirety).
- the present invention contemplates the use of any suitable semi-permeable membrane that allows the selected substance access to the bioreporter yet prevents the passage of larger molecules.
- U. S. Patent 4,944,659 (specifically incorporated herein by reference in its entirety), describes an implantable piezoelectric pump for drug delivery in ambulatory patients.
- U. S. Patent 5,474,552 specifically included herein in its entirety, describes an implantable pump for use in conjunction with a glucose sensor that can deliver multiple active agents, such as glucose, glucagon, or insulin as required. Separate pumps may be used for delivering each of the agents or a single pump that is switchable between them may be used.
- U. S. Patent 4,944,659 (specifically incorporated herein by reference in its entirety) describes an implantable piezoelectric pump for drug delivery in ambulatory patients.
- U. S. Patent 5,474,552 specifically included herein in its entirety, describes an implantable pump for use in conjunction with a glucose sensor that can deliver multiple active agents, such as glucose, glucagon, or insulin as required. Separate pumps may be used for delivering each of the agents or a single pump that is switchable between them may be used.
- Patent 5,569,186 specifcally inlcluded herein in its entirety, describes a closed loop infusion pump system controlled by a glucose sensor.
- the use of external drug delivery systems is contemplated in other embodiments of the present invention.
- U. S. Patent 5,800,420 specifically inlcuded herein in its sunflower, discloses a pump position topically against the skin surface that delivers a liquid drug, such as insulin, via a hollow delivery needle extending into the dermis.
- the drug delivery system may be interfaced with the biosensor device and controlled directly, as opposed to remote telemetry control, from the BBIC.
- the bioreporter for glucose monitoring will be a mammalian bioluminescent reporter cell line that has been genetically engineered to express luminescence in response to glucose concentrations on a continuos basis.
- An implantable bioluminescent sensor requires a bioluminescent reporter that can function without the exogenous addition of substrate for the luciferase reaction.
- Current eukaryotic luciferase systems used in molecular biology require the addition of exogenous substrate because of the complex nature for the production of eukaryotic luciferins. Cells must be either permeabilized or lysed and then treated with an assay solution containing luciferin. Thus current eukaryotic Iuciferases systems are not preferred candidates for on- line monitoring.
- bacterial lux genes The requirement for the addition of exogenous substrate can be obviated by the use of bacterial lux genes.
- the lux genes of X. luminescens, luxAB and luxCDE are used as the bioluminescent reporter system.
- the X. luminescens luxAB gene encodes the ⁇ - and ⁇ -subunits of a luciferase enzyme that exhibits greatest thermostability at 37°C, while other bacterial Iuciferases lose significant activity above 30°C.
- the luxCDE genes are required to eliminate the need for the addition of exogenous substrate.
- the aldehyde substrate of the luciferase encoded by the luxAB genes is generated by a fatty acid reductase complex coded for by the luxCDE genes.
- the preferred fatty acid for this reaction is myristic acid, which is present in eukaryotic organisms (Rudnick et al, 1993), and thus eukaryotic cells are suitable host cells for this reporter.
- the enzyme complex reduces the fatty acid to the corresponding aldehyde.
- the luciferase then oxidizes the aldehyde to back to the fatty acid.
- bioluminescence nucleic-acid segments may include the lux genes of Vibrio fischerii, luxCDABE, or Iuciferases from other organisms capable of bioluminescence that can be adapted so not as to require the addition of exogenous substrate.
- nucleic acid segment encodes green fluorescent protein of Aqueorea victoria or Renilla reniformis.
- One important embodiment of the invention is a recombinant vector that comprises one or more nucleic-acid segments encoding one or more bioluminescence polypeptides. Such a vector may be transferred to and replicated in a eukaryotic or prokaryotic host.
- a recombinant or heterologous promoter is intended to refer to a promoter that is not normally associated with a DNA segment encoding a crystal protein or peptide in its natural environment.
- a promoter that effectively directs the expression of the DNA segment in the cell type, organism, or even animal, chosen for expression.
- the use of promoter and cell type combinations for protein expression is generally known to those of skill in the art of molecular biology (see e.g., Sambrook et al, 1989). In a preferred embodiments of this, such promoters are directed by cw-acting glucose response elements.
- the glucose response element is the L4 box which directs the L-pyruvate kinase ("L-PK”) promoter in liver and islet ⁇ -cells.
- L-PK L-pyruvate kinase
- the L4 box consists of a tandem repeat of non-canonical E-boxes (Kennedy et al. 1997). Glucose enhances the hepatic and pancreatic ⁇ -cell by modifying the transactivating capacity of upstream stimulatory factors (“USF”) bound to the L4 box (Kennedy et al, 1997; Doiron et al,
- glucose controls the transactivational capacity of USF proteins is unclear.
- One possibility is the reversible phosphorylation of USF proteins.
- Glucose may alter the phosphorylation status through the pentose phosphate shunt via xyulose 5-phosphate (Dorion et al, 1996).
- An alternative mechanism is via the intracellular concentration of glucose 6-phosphate (Foufelle et al, 1992).
- Other glucose metabolites may also be implicated.
- Phosphorylated glucose metabolites include, but are not limited to, fructose 6-phosphate, 6-phosphogluconic acid, 6-phosphoglucono- ⁇ - lactone, ribulose 5-phosphate, ribose 5-phosphate, erythrose 4-phosphate.
- Non- phosphorylated glucose metabolites include, but are not limited to, citric acid, cis-aconixic acid, t/zreo-isocitric acid, succinic acid, fumaric acid, malic acid, oxaloacetic acid, pyruvic acid and lactic acid.
- glucose response element similar in arrangement to the L-PK gene L4 box, is the regulatory sequence involved in the transcriptional induction of the rat S14 gene (Shih et ⁇ l. 1995).
- Other glucose response elements that have been described include, but are not limited to, the hepatic 6-phosphofructo-2 -kinase gene (Dupriez and Rousseau. 1997), the ⁇ -islets insulin gene (German and Wang, 1994). the mesangial transforming growth factor-beta gene (Hoffman et ⁇ l, 1998), and the gene for acetyl- coenzyme-A carboxylase (Girard et ⁇ l., 1997).
- the present invention contemplates the use any glucose response element that can effectively direct a promoter or otherwise control the expression of the reporter protein in response to glucose.
- the recombinant vector comprises a nucleic-acid segment encoding one or more bioluminescence polypeptides.
- Highly preferred nucleic- acid segments are the lux genes of X. luminescens luxAB and luxCDE.
- Bacterial Iuciferases may have to be modified to optimize expression in eukaryotic cells. Almashanu et al. (1990) fused the luxAB genes from V.
- the fusion was successfully expressed in Saccharomyces cerevisiae and Drosophila melanogaster. The same strategy was used with luxAB from X. luminescens. The resultant construct has been sequenced to verify the genetic changes to generate the fusion and they were confirmed. The sequence of the fusion region is as follows:
- the fusion successfully expresses fused protein in E.coli and has been successfully cloned into the mammalian vector as described in Section 5.1.2.
- the inventors contemplate a recombinant vector comprising a nucleic-acid segment encoding one or more enzymes that are capable of producing a reaction that yields a luminescent product or a product that can be directly converted to a luminescent signal.
- a recombinant vector comprising a nucleic-acid segment encoding one or more enzymes that are capable of producing a reaction that yields a luminescent product or a product that can be directly converted to a luminescent signal.
- substrates of the commonly used ⁇ - galactosidase and alkaline phosphates enzymes are commercially available that are luminescent (chemiluminescence) when converted by the respective enzyme.
- the biosensor comprises at least a forst transformed host cell that expresses one or more of recombinant expression vectors.
- the host cell may be either prokaryotic or eukaryotic.
- the host cell is a mammalian cell.
- Host cells may include stem cells, ⁇ -islets cells or hepatocyte cells.
- the host cells are homologous cells, i.e. cells taken from the patient that are cultured, genetically engineered and then incorporated in the BBIC.
- Particularly preferred host cells are those which express the nucleic-acid segment or segments comprising the recombinant vector which encode the lux genes of X. luminescens, luxAB and luxCDE. These sequences are particularly preferred because the transcribed proteins of the X. luminescens lux system have the ability to function at 37°C (ambient human body temperature).
- a wide variety of ways are available for introducing a nucleic-acid segment expressing a polypeptide able to provide bioluminescence or chemiluminescence into the microorganism host under conditions that allow for stable maintenance and expression of the gene.
- the transcriptional initiation signals will include a promoter and a transcriptional initiation start site.
- nucleic-acid segment able to provide bioluminescence or chemiluminescence, where expression of the nucleic-acid segment will only occur after release into the proper environment.
- This can be achieved with operators or a region binding to an activator or enhancers, which are capable of induction upon a change in the physical or chemical environment of the microorganisms.
- an activator or enhancers which are capable of induction upon a change in the physical or chemical environment of the microorganisms.
- a ribosomal binding site and an initiation codon will be present.
- RNA RNA enhancing the expression of the messenger RNA may be employed, particularly by using an active promoter, as well as by employing sequences, which enhance the stability of the messenger RNA.
- the transcriptional and translational termination region will involve stop codon or codons, a terminator region, and optionally, a polyadenylation signal (when used in an Eukaryotic system).
- the construct will involve the transcriptional regulatory region, if any, and the promoter, where the regulatory region may be either 5' or 3' of the promoter, the ribosomal binding site, the initiation codon, the structural gene having an open reading frame in phase with the initiation codon, the stop codon or codons, the polyadenylation signal sequence, if any, and the terminator region.
- This sequence as a double strand may be used by itself for transformation of a microorganism host, but will usually be included with a DNA sequence involving a marker, where the second DNA sequence may be joined to the expression construct during introduction of the DNA into the host.
- marker the inventors refer to a structural gene that provides for selection of those hosts that have been modified or transformed.
- the marker will normally provide for selective advantage, for example, providing for biocide resistance (e.g., resistance to antibiotics or heavy metals); complementation, so as to provide prototrophy to an auxotrophic host and the like.
- biocide resistance e.g., resistance to antibiotics or heavy metals
- complementation so as to provide prototrophy to an auxotrophic host and the like.
- One or more markers may be employed in the development of the constructs, as well as for modifying the host.
- the construct will also include a sequence of at least 50 basepairs (bp), preferably at least about 100 bp, more preferably at least about 1000 bp, and usually not more than about 2000 bp of a sequence homologous with a sequence in the host.
- bp basepairs
- the nucleic-acid segment able to provide bioluminescence or chemiluminescence will be in close proximity to the gene providing for complementation as well as the gene providing for the competitive advantage. Therefore, in the event that the nucleic-acid segment able to provide bioluminescence or chemiluminescence is lost, the resulting organism will be likely to also have lost the complementing gene, and the gene providing for the competitive advantage, or both.
- transcriptional regulatory regions are available from a wide variety of microorganism hosts, such as bacteria, bacteriophage, cyanobacteria, algae, fungi, and the like.
- Various transcriptional regulatory regions include the regions associated with the trp gene, lac gene, gal gene, the ⁇ L and ⁇ R promoters, the tac promoter. See for example. U. S. Patent 4,332,898; U. S. Patent 4,342,832; and U. S.
- the termination region may be the termination region normally associated with the transcriptional initiation region or a different transcriptional initiation region, so long as the two regions are compatible and functional in the host.
- a fragment of the L-pyruvate kinase gene is used that contains the
- the p.LPK.LuCpp plasmid is used (Kennedy et al, 1997), with the exception that the luc gene coding for the firefly luciferase is removed and replaced with the fused X. luminescens luxAB genes.
- a plasmid will be employed which has a replication system that is functional in the host.
- the replication system may be derived from the chromosome, an episomal element normally present in the host or a different host, or a replication system from a virus that is stable in the host.
- plasmids are available, such as pBR322, pACYC184, RSF1010, pR01614, and the like. See for example, Olsen et al, 1982; Bagdasarian et al, 1981, and U. S. Patent 4,356,270, U. S. Patent 4,362,817, U. S. Patent 4,371,625, and U. S. Patent 5,441,884, each of which is incorporated specifically herein by reference.
- the desired gene can be introduced between the transcriptional and translational initiation region and the transcriptional and translational termination region, so as to be under the regulatory control of the initiation region.
- This construct will be included in a plasmid, which will include at least one replication system, but may include more than one, where one replication system is employed for cloning during the development of the plasmid and the second replication system is necessary for functioning in the ultimate host.
- one or more markers may be present, which have been described previously.
- the plasmid will desirably include a sequence homologous with the host genome.
- the transformants can be isolated in accordance with conventional ways, usually employing a selection technique, which allows for selection of the desired organism as against unmodified organisms or transferring organisms, when present. The transformants then can be tested for bioluminescence or chemiluminescence activity. If desired, unwanted or ancillary DNA sequences may be selectively removed from the recombinant bacterium by employing site-specific recombination systems, such as those described in U. S. Patent 5,441,884, specifically incorporated herein by reference in its entirety.
- the cells may be added to the BBIC any time from immediately to several h before implantation of the biosensor.
- the biosensor may alternatively consist of cells encapsulated in a polymeric matrix. Matrices will include materials previously shown to be successful in the encapsulation of living cells, including polyvinyl alcohol, sol-gel, and alginate (Cassidy et al, 1996).
- prokaryotic cell lines may be lyophilized in a freeze dry system (e.g., Savant) following the manufacturer's protocol.
- Lyophilization allows cells to undergo periods of long-term storage (several years) with a simple rehydration protocol being required for cell resuscitation prior to BBIC use (Malik et al. 1993). S. cerevisiae eukaryotic cells may be similarly lyophilized.
- Eukaryotic cell lines preferably consisting of islet ⁇ -cells, stem cells, or hepatic cells
- Eukaryotic cell lines may be encapsulated on the IC within polyvinyl alcohol mesh-reinforced or microporous filter supported hydrogels, which have previously been successfully implemented in these types of cell encapsulations (Baker et al, 1997; Burczak et al, 1996; Gu et aL, 1994; Inoue et ⁇ /., 1991).
- lyophilization is not an alternative.
- mammalian cells may be encapsulated in a sol gel or another immobilization matrix as previously described and attached to the BBIC.
- the completed BBIC in its enclosure would then be stored in serum or another appropriate maintenance medium and maintained until use.
- the advantage of using an immortal stem cell line is apparent for both long-term use and storage.
- Implantation may be performed according to the specific application. In the case of glucose detection, an area where interstitial fluid is accessible would be most appropriate. However an implantable device with the specific application of detecting hormones or other blood borne molecules would have to be accessible to the bloodstream.
- a synthetic vein or catheter system may need to be employed to allow continuous monitoring of the blood levels of the target molecule.
- a specific example other than glucose would be the use of the in vivo biosensor device to detect molecules associated with colon cancer. In this case the biosensor would be implanted in the colon.
- Integrated circuits may be individually packaged in sterile, static-proof bags.
- Prokaryotic-based and yeast eukaryotic biosensors consisting of lyophilized cells may be individually stored in sterile, static-proof, vacuum sealed bags for time periods approaching several years. Cells typically undergo rehydration in a minimal nutrient medium prior to use. Mammalian cell systems will remain frozen for long-term storage (up to 7 years at -150°C) or refrigerated for short-term storage (several days), either separately or. if entrapped, frozen or refrigerated in situ on the BBIC.
- cell viability may be checked be exposing the BBIC to a known concentration of the analyte of interest, thus producing a quantitative bioluminescent signal of known magnitude.
- One or more control vials of analyte(s) or reference “standards" may be included as part of a diagnostic kit, or may be supplied for proper calibration of the implantable device.
- the BBIC analyte biosensor is implanted such that it is contact with the interstitial fluid of the animal.
- the interstitial fluid of the animal For example, in the case of glucose biosensors, it has been shown that glucose kinetics in interstitial fluid can be predicted by compartmental modeling (Gastaldelli et al, 1997). In particular the subcutaneous placement of glucose sensors has been demonstrated (Schmidt et al, 1993; Poitout et al, 1993; Ward et al, 1994; Stenberg et al, 1995; Bantle and Thomas, 1997).
- the implantable biosensor may be placed in any convenient location throughout the body using conventional surgical and implant methodologies.
- the device may be implanted in such as way as to be in contact with interstitial fluid, lymph fluid, blood, serum, synovial or cerebrospinal fluid depending upon the particular analyte to be detected.
- the implantable device msy be placed in contact with particular tissues, organs, or particular organ systems.
- the present invention also contemplates the use of multiple biosensors for the detection of a plurality of different analytes.
- one or more devices may be used to monitor various glucose or glucose metabolites, glucagons, insulin, and the like.
- one or more biosensor devices may be employed in controlled drug delivery systems.
- the device may be operably connected to a drug delivery pump or device that is capable of being controlled by the biosensor and that is able to introduce into the body of the animal an amount of a particular drug, hormone, protein, peptide, or other pharmaceutical composition determined by the concentration of one or more analytes detected by the BBIC device.
- controlled drug delivery systems are contemplated by the inventors to be particularly desirable in providing long-term administration of drugs to an animal such as in the case of chronic or life-long medical conditions or where symptoms persist for a long period of time.
- the long term controlled delivery of drugs such as pain medications, heart or other cardiac regulators, diuretics, or homones or peptides such as insulin, or metabolites such as glucagon or glucose can be facilitated by such biosensor/pump systems.
- multiple drug delivery systems or a single switchable drug delivery system is contemplated to be particularly useful.
- the BBIC glucose sensor may be used for monitoring glucose in diabetic patients.
- a sensor can also be used in other conditions where glucose concentrations are of concern, such as in endurance athletes or other condition involving either hypo- or hyperglycemia.
- Such measurements may be the end point for investigative or diagnostic purposes or the sensors may be linked via telemetry or directly to a drug delivery system.
- implantable BBICs for substances other than glucose can be used in a range of therapeutic situations. With the incorporation of an appropriate c/s-activating response element.
- BBICs could monitor a number of substances and could find use in chronic pain treatment, cancer therapy, chronic immunosuppression, hormonal therapy, cholesterol management, and lactate thresholds in heart attack patients.
- Section 5.7 describes the use of the BBICs in the detection and diagnosis of cancer.
- biosensors can be calibrated to check for viability of the cells as well as performance.
- the calibration is performed by exposing the sensor to solutions containing varying concentrations of the analyte(s) of interest.
- the bioreporter may be calibrated by a series of standard analyte concentrations for the specific application after its initial construction.
- the overall on-line performance can be monitored using microfluidics with a reservoir of the analyte, which would systematically provide a known concentration to the cells this would allow both calibration and test for viability.
- the luminescence response is then correlated to concentration and the parameters set. Viability can also be continuously monitored by bioengineered cells in which the reporter exhibits continuous luminescence. Loss of viability results in decreased luminescence. This technique has been used to detect the viability of prokaryotic cells.
- the BBIC would contain two bioreporters, the bioreporter detecting the selected substance and the second bioreporter exhibiting a luminescence proportional to cell viability. Measurement of the ratio of the signals from the two bioreporters would give a detection method that would automatically correct for any loss in viability.
- the bioreporters can be stored in the appropriate maintenance medium (e.g., standard tissue culture media, sera, or other suitable growth or nutrient formulations), and then calibrated prior to implantation.
- the viability of the devices may be checked by bioluminescence using microfluidics, or by the quantiation of known standards or other reference solutions to ensure viability and integrity of the system prior to, or after implantation.
- the monolithic biosensor devices may be used external to the body of the monitored individual. In some clinical settings the monitor may be used to monitor glucose in body fluids in an extracorporeal fashion. The device may even be used in the pathological or forensic arts to detect the quantity of particular analytes in body tissues or fluids and the like.
- the present invention also contemplates use of the biosensor devices in the veterinary arts. Implantation of such devices in animals for the monitoring of hormone levels in the blood (i.e. for optimizing milk production), monitoring the onset of estrous (heat) in numerous animals to maximize artificial insemination efficiency, and monitoring hormone levels in the milk produced online (in the udder) etc. is contemplated to provide particular benefits to commercial farming operations, livestock industries and for use by artisans skilled in veterinary medicine.
- kits may comprise, in suitable container means, one or more bioreporters and an integrated circuit including a phototransducer.
- the kit will also preferably contain instructions for the use of the biosensor apparatus, and may further, optionally comprise a drug delivery device or a second biosensor apparatus.
- the kit may comprise a single container means that contains one or more bioreporters and the integrated circuit including a phototransducer and drug delivery device.
- the kits of the invention may comprise distinct container means for each component.
- one container would contain one or more bioreporters, either in an appropriate medium or pre-encapsulated in a polymer matrix, another container would include the integrated circuit, and another conatiner would include the drug delivery device.
- the kit may contain one or more encapsulation media.
- the use of distinct container means for each component would allow for the modulation of various components of the kits. For example, several bioreporters may be available to choose from, depending on the substance one wishes to detect. By replacing the bioreporter, one may be able to utilize the remaining components of the kit for an entirely different purpose, thus allowing reuse of components.
- the container means may be a container such as a vial, test tube, packet, sleeve, shrink-wrap, or other container means, into which the components of the kit may be placed.
- the bioreporter or any reagents may also be partitioned into smaller containers or delivery vehicles, should this be desired.
- the kits of the present invention also may include a means for containing the individual containers in close confinement for commercial sale, such as, e.g., injection or blow-molded plastic containers into which the desired components of the kit are retained. Irrespective of the number of containers, the kits of the invention also may comprise, or be packaged with, an instrument for assisting with the placement of the bioreporter upon the integrated circuit.
- kits may be a syringe, pipette, forceps, or any other similar surgical or implantation device.
- the kit may also comprise one or more stents, catheters, or other surgical instrument to facilitate implantation within the body of the target animal.
- kits may also comprise devices for remote telemetry or devices for data storage or long term recordation of the data obtained from the monitoring device.
- the kits may comprise one or more drug delivery pumps as described above, and may also comprise one or more pharmaceutical agents themselves for administration.
- the system would typically comprise a glucose- sensitive BBIC device, a drug delivery pump, instructions for the implantation and/or use of the system, and optionally, reference standards or pharmaceutical formulations of insulin, glucagon or other pharmaceutical composition.
- the system may also optionally comprise growth and/or storage medium to support the nutritive needs of the bioreporter cells comprised within the BBIC device.
- the firefly luciferase has been used in examining the regulation of L-pyruvate kinase promoter activity in single living rat islet ⁇ -cells (Kennedy et al, 1997). However, these cells had to be perfused with Beetle luciferin in order to generate a luminescence response.
- a preferred bioluminescent reporter system for the present invention is one that does not require the addition of exogenous substrate.
- this may be accomplished using the bioluminescent genes from X. luminescens.
- luxA and luxB genes or a single fused luxAluxB gene encode the ⁇ - and ⁇ -subunits. respectively, of the luciferase enzyme (Meighen et al, 1991).
- This luciferase exhibits greatest thermostability at 37°C while other bacterial Iuciferases lose significant activity above 30°C Therefore, these bacterial Iuciferases can be expressed in eukaryotic cells with slight modification.
- the substrate is generated by a fatty acid reductase complex encoded by the luxCDE genes. This enzyme complex reduces short chain fatty acids to the corresponding aldehyde. The luciferase then oxidizes the aldehyde to the corresponding fatty acid.
- the preferred fatty acid for this reaction is myristic acid, which is present in eukaryotic organisms (Rudnick et al, 1993). Myristic acid is usually involved in the myristoylation of the amino terminus that is associated with membrane attachment (Borgese et al, 1996, Brand et al, 1996).
- the biosensor also preferably comprises a nucleic acid sequence that encodes the three luxC, luxD, and /z E-encoded subunits.
- the luxC, luxD, and luxE genes have been fused to produce a single luxCDE gene fusion that encodes the three subunits of the enzyme complex. The methods of preparing such gene fusions are described below:
- the luxAB genes may be fused using conventional molecular biology techniques. For example, the polymerase chain reaction may be routinely employed for this purpose. By synthesizing a 5'-primer whose sequence begins with ATG for the start codon for the luxA gene juxtaposed by a 3 '-primer ending with the codon immediately preceding the ATT stop codon. These primers may then be used in amplification reactions and the product gel purified.
- the luxB gene may also be amplified as above using primers that eliminate the ATG initial methionine codon but preserve the reading frame.
- the PCRTM reactions employ a thermostable polymerase such as the PfuTM polymerase of Stratagene (La Jolla, CA), which does not have terminal deoxytransferase activity and therefore generates a blunt end.
- the resultant PCRTM products are blunt-end ligated, and the ligation is then subjected to PCRTM using the 5'-primer from luxA and the 3'-primer from luxB using Taq polymerase to facilitate TA cloning (Invitrogen, San Diego, CA). Only ligations with the correct orientation of fragments are amplified.
- the luxAB amplicon is then gel purified and TA cloned into a suitable vector (such as the PCRIITM vector) and transformed into E. coli using standard manufacturer's protocols.
- Transformants are screened for light production by the addition of «-decanal which, when oxidized by the luciferase, generates bioluminescence. Only colonies emitting light are selected since they are in the proper orientation for further genetic manipulation.
- the luxCDE fusion is generated using the same strategy as above except transformants are screened by minipreps followed by restriction digestion analysis to determine orientation. Plasmids are amplified in E. coli, recovered and purified twice on CsCl gradients.
- cloned fragments containing luxAB are cloned into a suitable mammalian expression vector (such as pcDNA 3.1 and /uxCDE-containing fragments are cloned into a suitable mammalian expression vector (such as pcDNA/Zeo 3.1) (Invitrogen, Faraday, CA). Both vectors constitutively express inserted genes. HeLa cells are then transfected with luxAB or both luxAB and luxCDE and selected using appropriate antibiotics following the manufacturer's protocol (Promega, Madison, WI).
- the firefly luciferase has been used in examining the regulation of L-pyruvate kinase promoter activity in single living islet ⁇ -cells (Kennedy et al, 1997).
- a glucose response element designated the L4 box has been determined to be in the proximal promoter.
- a 200-bp fragment containing this region was cloned in front of the firefly luciferase (luc) in plasmid pGL3Basic resulting in a glucose reporter plasmid designated p.LPK.Luc FF . Results resulted in the detection of single cells that were exposed to 16 mM glucose but not 3 mM glucose.
- the bioluminescent reporter plasmid was constructed by removing the luc gene coding for the firefly luciferase from p.LPK.LuCpp and replacing it with the fused luxAB gene. This was accomplished by cleaving the luc gene from p.LPK.Lucpp and cloning in the luxAB gene. The resultant plasmid was amplified in E. coli and the plasmid DNA extracted and double purified on CsCl gradients.
- Islet cells were prepared as previously described (German et al, 1990) and transfected by electroporation with the bioluminescent reporter construct and the plasmid containing the constitutively expressed luxCDE construct. This configuration causes the cells to maintain a pool of the aldehyde substrate that is available to the reporter genes (luxAB).
- luxAB reporter genes
- Cells were screened for light production in a range of glucose concentrations from 3 mM to 30 mM.
- Transfected cells were washed, concentrated, and placed in a microwell in a light-tight cell that is then affixed to the integrated circuit. Different concentrations of glucose and assay media (Kennedy et al, 1997) were added to the cells to examine sensitivity and response time of the glucose BBIC.
- reporter gene technology is widespread in studying gene regulation in both eukaryotic and prokaryotic systems.
- Various genes are used depending on the cell lines being investigated.
- reporter genes coding for bioluminescence are utilized.
- All previously developed reporters utilizing other reporter genes for example the gene coding for ⁇ -galactosidase (lacZ) may be converted to the bioluminescent version using standard molecular techniques and the reporter genes utilized in this specific application (modified lux system). Therefore, any currently existing reporter cell line for testing gene expression in mammalian cell lines may be adapted for use as a bioreporter when converted to the lux reporter.
- the implantable system simply contains the appropriate reporter cell line. Table 1 shows a list of examples of eukaryotic reporter cell lines that may be exploited in an implantable biosensor.
- a pair of bioluminescent reporters may be utilized that are in tandem and that specifically respond to deviations in glucose concentrations.
- One bioreporter utilizes the luxAB and luxCDE genes from X. luminescens incorporated into a plasmid-based system designated p.LPK.LuCpp, which contains a eukaryotic luc gene able to respond to glucose concentrations (increasing bioluminescence corresponds to increasing glucose concentrations).
- the second bioreporter utilizes a plasmid construct containing the promoter for the phosphoenolpyruvate carboxylase gene (PEPCK) that also responds to glucose concentrations, except increased bioluminescence corresponds to decreased levels of glucose.
- PEPCK phosphoenolpyruvate carboxylase gene
- the integrated circuit comprises separate photodetector units for each bioreporter (FIG. 9A, FIG. 9B, and FIG. 9C).
- Bioluminescent responses from each construct can be independently monitored, allowing for the signal processing circuitry to differentiate between one bioreporter' s response to increased glucose concentrations and the second bioreporter' s response to decreased glucose concentrations.
- the signal processing circuitry processes the signals from the photodetectors, converts it to a digital format and relays the information to the implanted insulin pump (FIG. 10).
- the tandem set of bioreporters allows a more accurate signal as well as redundancy in the detector. Due to the often-fatal outcome of hypoglycemia, this tandem system also allows for more careful monitoring and warning of the onset of hypoglycemia.
- the cells used in the tandem bioreporter system may be affixed to each of the photodetectors either directly by attachment or encapsulated in hydrogel (Prevost et al, 1997). It may be necessary to isolate the bioreporters using a semi-permeable membrane to allow the transport of small molecules such as glucose and insulin across the membrane and prohibit the influx of immune effector cells and antibodies (Monaco et al, 1993,
- bioluminescent reporter cell lines may be constructed from cells taken directly from the patient to receive the implant. This approach is particularly desirable in cases of long-term implants such as implantable insulin delivery.
- Cells may be obtained from the patient, genetically engineered for the appropriate monitoring function, grown in cell culture, evaluated and then preserved for long-term storage.
- the use of cell lines developed from the patient's own cells, is particularly desirable as it reduces the chance of host rejection and creation of an immune response to the implanted device.
- stem cells immortal stem cells, if attainable
- pluripotent, totipotent, or otherwise immortal cell lines provide particular advantage in the creation of suitable long-term implantable devices.
- the biosensor Before implantation the biosensor may be calibrated injecting the chamber containing the cells with various concentrations of glucose delivered from an auxiliary pump and reservoir on the insulin delivery pump (FIG. 10). This permits determination of the appropriate parameters to allow the proper dosage of insulin to be delivered. Once the parameters are set, the pump may be evaluated for insulin delivery. Systematically the glucose biosensor is recalibrated in the patient utilizing the glucose standard contained in the delivery' pump. In the case of drug delivery systems, the glucose biosensor may be operably connected to the delivery pump via a hardwire or wireless connection. The biochip provides digital data that may be input directly to the signal processing circuitry of the pump to proportionally dispense the insulin. Alternatively, the digital data may be converted into analog data and used to control the pump.
- the patient may place a radio transmitter/receiver outside the body near the implanted device to communicate the data from the implanted device toa remote station.
- the radio transmitter/receiver may be linked to a computer programmed to forward the data to a remote station over a network such as a local area network, a wide area netword, or even the Internet.
- a network such as a local area network, a wide area netword, or even the Internet.
- the Medtronic Synchronized infusion system may be used as it has extensively used in drug delivery and utilizes a portable computer to allow programming of the pump from outside the body (www.asri.edu/neuro/brochure/pain6.htm).
- the pump can also be refilled through the skin via a self-sealing septum.
- the pump is one inch thick and three inches in diameter and weighs approximately six ounces.
- the biosensor can be integrated into the preexisting electronic circuitry to take advantage of the out-of-body programming by a portable computer.
- the chip can be powered utilizing the battery that powers the delivery pump.
- the biosensor/insulin pump apparatus may be surgically implanted using local anesthesia in the abdominal cavity. Both the sensor and the pump may be implanted in the peritoneal space of the abdomen both for simplicity and to avoid the complications of direct catheter placement in the blood stream. Glucose concentrations are monitored and the insulin delivered peritoneally as required by the patient (FIG. 10).
- PEPCK gene expression is increased in the presence of glucocorticoids and cAMP and decreased in the presence of insulin (Sasaki et al, 1984; Short et al, 1986). In both rat liver and H4IIE hepatoma cells the insulin effect is dominant and the glucocorticoids and cAMP is additive.
- the promoter region of the PEPCK will be cloned in front of the fused luxAB. The resultant construct will then produce increased bioluminescence in the presence of low glucose concentrations.
- the bioluminescent reporter plasmid for detecting increased glucose concentration may be constructed by removing the luc gene coding for the firefly luciferase from p.LPK.Lucpp and replacing it with the fused luxAB. This is accomplished by cleaving the luc gene from p.LPK.LuCpp and cloning in the luxAB gene.
- the bioluminescent reporter plasmid for the detection of low glucose concentrations is constructed by replacing the chloramphenicol transferase (CAT) gene in the previously constructed PEPCK promoter CAT fusion (Petersen et al, 1988; Quinn et al, 1988) with the luxAB gene. The resultant plasmid is amplified in E. coli and the plasmid DNA extracted and double purified on CsCl gradients.
- CAT chloramphenicol transferase
- Islet and hepatoma cells may be prepared as previously described (German et al, 1990; Petersen et al, 1988) and co-transfected with the bioluminescent reporter construct and the plasmid containing the constitutively expressed luxCDE gene constructed in objective one. This configuration causes the cells to maintain a pool of aldehyde substrate that will be available to the reporter genes (luxAB). Cells are screened for light production in a range of glucose concentrations from 3 mM to 30 mM. Transfected cells are washed, concentrated, and placed in a microwell in a light-tight chamber that is then affixed to the integrated circuit.
- glucose and assay media Different concentrations of glucose and assay media (Kennedy et al, 1997) are added to the cells to examine sensitivity and response time of the glucose BBIC. After initial characterization, the bioluminescent glucose reporters may also be tested in a flow cell. Cells are placed in an encapsulation medium on the integrated circuit and media containing different concentrations of glucose (3-to-30 mM) is then perfused across the cells to examine dynamic responses.
- Colon cancer is the second leading cause of cancer death after lung cancer in the United States, and the incidence increases with age in that 97% of colon cancer occurs in persons greater than 40 (Coppola and Karl, 1998). Although most cases of colon cancer are sporadic, in 15% of the patients there is a strong familial history of similar tumors in first-degree relative relatives (Coppola and Karl, 1998). These familial cancers such as hereditary nonpolyposis colon cancer (HNPCC) and familial adenomatous polyposis (FAP) result from autosomal dominant inheritable genetic mutations in putative tumor suppressor genes, and a spectrum of lesions occurs from hyperplasia-dysplasia-adenoma- carcinoma (Coppola and Karl, 1998). Because much of the early molecular lesions are known about inherited colonic cancer, they represent a useful model for development of a novel biosensor strategy for early clinical detection. Biosensors are hybrid devices combining a biological component with a computerized measuring transducer.
- HNPCC hereditary nonpol
- This example describes the adaptation of the implantable biosensor device to permit early detection of cancers, and to permit means for monitoring remission and recurrence of cancer. Because the miniaturized biosensors of the present invention are small enough to be implantable, and can be combined with a reporter system engineered to produce light without the need for cellular lysis or additional substrate, a powerful tool for early diagnosis of colon cancer in the form of an implantable device is now possible for the first time.
- the inducible reporter system utilized is based on the luxAB and luxCDE genes from X. luminescens placed in a eukaryotic reporter cell so that expression of certain genes or their products can be detected by expression of bioluminescence by the BBICdevice.
- the eukaryotic reporter cell is treated with mitomycin C so it is unable to divide, but is still able to respond metabolically and produce a quantitative bioluminescent signal.
- Colon cancer is the second leading cause of cancer death in the United Sates, with at least 50% of the population developing a colorectal tumor by the age of 70 (Kinzler and
- Familial adenomatous polyposis is a syndrome characterized by the development of hundreds to thousands of adenomas or polyps in the colon and rectum, only a small number of which develop into invasive cancer (Kinzler and Vogelstein, 1996).
- Loss of function of both alleles of the adenomatous polyposis coli (APC) tumor suppressor gene predisposes persons to develop malignant cancer (Coppola and Marks, 1998).
- the APC gene encodes a cytoplasmic protein that localizes to the ends of microtubules at focal adhesion complexes (Kinzler and Vogelstein, 1996). As cells migrate up through the crypts, expression of APC increases until the terminally differentiated and located colonic epithelial cells undergo apoptosis (Kinzler and Vogelstein. 1996). Cadherins are transmembrane proteins that are localized to focal adhesion plaques in most epithelial cells (Aplin et al, 1998). The carboxy terminus of each cadherin interacts with cytoplasmic structural proteins known as catenins (Aplin et al, 1998).
- ⁇ -catenin binds to the cytoplasmic domain of cadherin; -catenin binds to ⁇ -catenin and the actin cytoskeleton via -actinin; -catenin functions in place of ⁇ -catenin in some cell types (Aplin et al, 1998).
- ⁇ -Catenin also is part of a signal transduction pathway involving the secreted glycoprotein Wnt and glycogen synthase kinase 3 (GSK3) (Aplin et al, 1998).
- APC interacts with several components of the Wnt- ⁇ -catenin-GSK3 pathway, including ⁇ - and ⁇ -catenins, GSK3, and tubulin (Aplin et al. 1998). Most of the mutations in colorectal cancer are in the carboxy terminal region of APC so that it can no longer bind ⁇ -catenin (Aplin et al, 1998). In fact, -catenin lies downstream of APC and is critical for its function as a tumor suppressor gene (Aplin et al, 1998). When the Wnt pathway is inactivated, GSK3 phosphorylates the N-terminus of ⁇ -catenin, targeting it for degradation by the ubiquitin pathway (Munemitsu et al, 1996).
- ⁇ -catenin When ⁇ -catenin accumulates, it activates gene transcription via the transcription factor Lef-1/TCF (Morin et al, 1997). APC works in concert with GSK3 to inhibit -catenin-mediated transcriptional activity (Kinzler and Vogelstein, 1996).
- microsatellite instability is the result of mutations in one or more DNA-mismatch repair genes (Jiricny 1998; Nicholaides et al,
- HNPCC tumors have microsatellite instability (Karran 1996; Smyrk 1994).
- One potential marker for microsatellite instability in colorectal tumors is inactivation of the type II receptor for TGF- ⁇ (Markowitz et al, 1995).
- Loss of function of ⁇ RII is associated with loss of growth regulation and tumor progression in colorectal adenomas in HNPCC (Wang et al, 1995).
- Other signaling components of the TGF- ⁇ pathway that are involved in colorectal tumorigenesis include mutations in Smad 3 and Smad 4, both of which result in the development of colorectal adenocarcinomas in mice
- Tcf T cell transcription factor
- the cells are attached to the biosensor chip. It is necessary to insure that these cells are incapable of dividing, so after transfection and selection, the cells are irradiated with 6,000 rads ⁇ -radiation from a 60 Co source (UT College of Veterinary Medicine). In some embodiment it may be necessary to attach the cells to the biochip prior to irradiation so that efficient attachment can occur. An alternative is to treat the cells with mitomycin C to prevent further mitosis. Biochips may be coated with Matrigel, a basement membrane material that promotes attachment of epithelial cells.
- Tcf T cell transcription factor
- the present invention also provides a biosensor that may be used for endoscopic screening of the colonic mucosa to detect the presence of mutated cells prior to the onset of gross morphological alterations. It may be necessary to attempt detection of more than one abnormality at a time for the degree of sensitivity needed to detect small foci of malignant transformation. For example, many colonic tumors, especially those with mutations in APC, overexpress cyclooxygenase-2 (COX-2) and secrete large amounts of prostaglandins (Kutchera et al, 1996; Sheng et al, 1997: Coffey et al, 1997; Kinzler and
- Cyclooxygenase-2 is an early response gene that not constitutively expressed, but is turned on in colonic epithelial cells by growth factors and tumor promoters (Kutchera et al, 1996; Sheng et al, 1997; Coffey et al, 1997). It may be possible to bioengineer reporter cells to bioluminesce in the presence of increased levels of prostaglandins in the intestinal lumen. Prostaglandins freely pass the cell membrane and would be able to enter the cytoplasm of the reporter cell to activate a reporter construct.
- TGF- Transforming growth factor- (TGF- )-induced down- regulation of cyclin A expression requires a functional TGF- receptor complex.
- Bioreporter Integrated Circuits (BBICs) Bioluminescent Bioreporter Integrated Circuits (BBICs): Whole-Cell Environmental Monitoring Devices," to be presented at the 29th International Conference on Environmental Systems, July 15, 1999.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002352571A CA2352571C (en) | 1998-12-02 | 1999-12-02 | In vivo biosensor apparatus and method of use |
KR1020017006949A KR20010102951A (en) | 1998-12-02 | 1999-12-02 | In vivo biosensor apparatus and method of use |
AU20408/00A AU762948B2 (en) | 1998-12-02 | 1999-12-02 | In vivo biosensor apparatus and method of use |
EP99964095A EP1135677A1 (en) | 1998-12-02 | 1999-12-02 | In vivo biosensor apparatus and method of use |
JP2000585651A JP2002531194A (en) | 1998-12-02 | 1999-12-02 | In vivo biosensor device and method of use |
HK02102125.2A HK1040767A1 (en) | 1998-12-02 | 2002-03-20 | In vivo biosensor apparatus and method of use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11068498P | 1998-12-02 | 1998-12-02 | |
US60/110,684 | 1998-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000033065A1 true WO2000033065A1 (en) | 2000-06-08 |
Family
ID=22334332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/028733 WO2000033065A1 (en) | 1998-12-02 | 1999-12-02 | In vivo biosensor apparatus and method of use |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1135677A1 (en) |
JP (1) | JP2002531194A (en) |
KR (1) | KR20010102951A (en) |
AU (1) | AU762948B2 (en) |
CA (1) | CA2352571C (en) |
HK (1) | HK1040767A1 (en) |
WO (1) | WO2000033065A1 (en) |
Cited By (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002014551A2 (en) * | 2000-08-14 | 2002-02-21 | The University Of Tennessee Research Corporation | Bioluminescent methods for direct visual detection of environmental compounds |
WO2002013686A1 (en) * | 2000-08-11 | 2002-02-21 | Dexcom Inc. | Systems and methods for remote monitoring and modulation of medical devices |
WO2002027294A2 (en) * | 2000-09-29 | 2002-04-04 | Michele Delsanter | Multifunctional and multiparametric biochip arrangement |
WO2002039112A2 (en) * | 2000-11-09 | 2002-05-16 | Sicel Technologies, Inc. | In vivo detection of biomolecule concentrations using fluorescent tags |
WO2002087429A1 (en) * | 2001-04-27 | 2002-11-07 | Novartis Ag | Apparatus for measuring blood glucose concentrations |
WO2003051191A1 (en) * | 2001-12-17 | 2003-06-26 | Danfoss A/S | Method and device for monitoring analyte concentration by optical detection |
JP2005525139A (en) * | 2001-10-23 | 2005-08-25 | メドトロニック ミニメド インコーポレイテッド | Method and system for non-vascular sensor implantation |
JP2006500170A (en) * | 2002-09-27 | 2006-01-05 | メドトロニック ミニメド インコーポレイテッド | Implantable sensor method and system |
DE102005027245A1 (en) * | 2005-06-13 | 2006-12-21 | Siemens Ag | CMOS (complementary metal oxide semiconductor) circuit arrangement has operating circuit region with decoder to address at least one of sensor and actuator elements, and evaluation and driver circuits for sensor and actuator elements |
US7647112B2 (en) | 2004-02-11 | 2010-01-12 | Ethicon, Inc. | System and method for selectively stimulating different body parts |
US7778695B2 (en) | 2003-02-19 | 2010-08-17 | Sicel Technologies, Inc. | In vivo fluorescence sensors, systems, and related methods operating in conjunction with fluorescent analytes |
US7979137B2 (en) | 2004-02-11 | 2011-07-12 | Ethicon, Inc. | System and method for nerve stimulation |
USRE43039E1 (en) | 2003-12-05 | 2011-12-20 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8165695B2 (en) | 2004-02-11 | 2012-04-24 | Ethicon, Inc. | System and method for selectively stimulating different body parts |
JP2013517029A (en) * | 2010-01-13 | 2013-05-16 | ユニヴェルシテ ド ボルドー アン | Sensor for measuring activity of pancreatic β cells or islets of Langerhans, manufacture and use of such sensor |
US8690775B2 (en) | 2004-07-13 | 2014-04-08 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8751003B2 (en) | 2004-02-11 | 2014-06-10 | Ethicon, Inc. | Conductive mesh for neurostimulation |
US8843187B2 (en) | 2003-08-22 | 2014-09-23 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8840552B2 (en) | 2001-07-27 | 2014-09-23 | Dexcom, Inc. | Membrane for use with implantable devices |
US8840553B2 (en) | 1998-04-30 | 2014-09-23 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8845536B2 (en) | 2003-08-01 | 2014-09-30 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8865249B2 (en) | 2002-05-22 | 2014-10-21 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US8886273B2 (en) | 2003-08-01 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US8886272B2 (en) | 2004-07-13 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US8915850B2 (en) | 2005-11-01 | 2014-12-23 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8915849B2 (en) | 2003-08-01 | 2014-12-23 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8923947B2 (en) | 1997-03-04 | 2014-12-30 | Dexcom, Inc. | Device and method for determining analyte levels |
US8920319B2 (en) | 2005-11-01 | 2014-12-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8930203B2 (en) | 2007-02-18 | 2015-01-06 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
US8926585B2 (en) | 2004-02-26 | 2015-01-06 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US8933664B2 (en) | 2006-03-31 | 2015-01-13 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
US8954128B2 (en) | 2008-03-28 | 2015-02-10 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US8968198B2 (en) | 2006-02-22 | 2015-03-03 | Dexcom, Inc. | Analyte sensor |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8986209B2 (en) | 2003-08-01 | 2015-03-24 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8993331B2 (en) | 2009-08-31 | 2015-03-31 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods for managing power and noise |
US9000929B2 (en) | 2007-05-08 | 2015-04-07 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US9011332B2 (en) | 2001-01-02 | 2015-04-21 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9020572B2 (en) | 2008-02-21 | 2015-04-28 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
US9035767B2 (en) | 2007-05-08 | 2015-05-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US9039975B2 (en) | 2006-03-31 | 2015-05-26 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
US9055901B2 (en) | 2004-07-13 | 2015-06-16 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9066709B2 (en) | 2009-01-29 | 2015-06-30 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9078607B2 (en) | 2005-11-01 | 2015-07-14 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9078608B2 (en) | 2005-03-10 | 2015-07-14 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US9095290B2 (en) | 2007-03-01 | 2015-08-04 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
US9107623B2 (en) | 2003-12-09 | 2015-08-18 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US9135402B2 (en) | 2007-12-17 | 2015-09-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9149233B2 (en) | 2007-12-17 | 2015-10-06 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9155496B2 (en) | 1997-03-04 | 2015-10-13 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US9177456B2 (en) | 2007-05-08 | 2015-11-03 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US9173607B2 (en) | 2008-03-28 | 2015-11-03 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US9226701B2 (en) | 2009-04-28 | 2016-01-05 | Abbott Diabetes Care Inc. | Error detection in critical repeating data in a wireless sensor system |
US9247901B2 (en) | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
US9282925B2 (en) | 2002-02-12 | 2016-03-15 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9314195B2 (en) | 2009-08-31 | 2016-04-19 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
US9320461B2 (en) | 2009-09-29 | 2016-04-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
US9320466B2 (en) | 2009-07-02 | 2016-04-26 | Dexcom, Inc. | Analyte sensor |
US9323898B2 (en) | 2005-11-04 | 2016-04-26 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
US9328371B2 (en) | 2001-07-27 | 2016-05-03 | Dexcom, Inc. | Sensor head for use with implantable devices |
US9339222B2 (en) | 2008-09-19 | 2016-05-17 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US9339223B2 (en) | 1997-03-04 | 2016-05-17 | Dexcom, Inc. | Device and method for determining analyte levels |
US9446194B2 (en) | 2009-03-27 | 2016-09-20 | Dexcom, Inc. | Methods and systems for promoting glucose management |
US9451908B2 (en) | 2006-10-04 | 2016-09-27 | Dexcom, Inc. | Analyte sensor |
US9451910B2 (en) | 2007-09-13 | 2016-09-27 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9477811B2 (en) | 2001-04-02 | 2016-10-25 | Abbott Diabetes Care Inc. | Blood glucose tracking apparatus and methods |
US9504413B2 (en) | 2006-10-04 | 2016-11-29 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US9538946B2 (en) | 2003-11-19 | 2017-01-10 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
US9549693B2 (en) | 2002-05-22 | 2017-01-24 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US9574914B2 (en) | 2007-05-08 | 2017-02-21 | Abbott Diabetes Care Inc. | Method and device for determining elapsed sensor life |
US9717449B2 (en) | 2007-10-25 | 2017-08-01 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9730584B2 (en) | 2003-06-10 | 2017-08-15 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
US9741139B2 (en) | 2007-06-08 | 2017-08-22 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US9757061B2 (en) | 2006-01-17 | 2017-09-12 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US9763609B2 (en) | 2003-07-25 | 2017-09-19 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US9775543B2 (en) | 2004-07-13 | 2017-10-03 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9788766B2 (en) | 2005-04-15 | 2017-10-17 | Dexcom, Inc. | Analyte sensing biointerface |
US9833143B2 (en) | 2004-05-03 | 2017-12-05 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9895089B2 (en) | 2003-08-01 | 2018-02-20 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US9968306B2 (en) | 2012-09-17 | 2018-05-15 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
US9980669B2 (en) | 2011-11-07 | 2018-05-29 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods |
US10022078B2 (en) | 2004-07-13 | 2018-07-17 | Dexcom, Inc. | Analyte sensor |
US10039881B2 (en) | 2002-12-31 | 2018-08-07 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
US10278580B2 (en) | 2004-02-26 | 2019-05-07 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US10300507B2 (en) | 2005-05-05 | 2019-05-28 | Dexcom, Inc. | Cellulosic-based resistance domain for an analyte sensor |
US10376143B2 (en) | 2003-07-25 | 2019-08-13 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US10478108B2 (en) | 1998-04-30 | 2019-11-19 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
CN110940714A (en) * | 2018-09-21 | 2020-03-31 | 罗斯蒙特公司 | Analyzing predicted lifetime of a sensor |
US10602968B2 (en) | 2008-03-25 | 2020-03-31 | Dexcom, Inc. | Analyte sensor |
US10653835B2 (en) | 2007-10-09 | 2020-05-19 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US10791928B2 (en) | 2007-05-18 | 2020-10-06 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US20210045660A1 (en) * | 2019-08-12 | 2021-02-18 | Efferent Labs, Inc. | Wearable devices for monitoring physiological changes and methods of use |
US10980461B2 (en) | 2008-11-07 | 2021-04-20 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US11000215B1 (en) | 2003-12-05 | 2021-05-11 | Dexcom, Inc. | Analyte sensor |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
US11350862B2 (en) | 2017-10-24 | 2022-06-07 | Dexcom, Inc. | Pre-connected analyte sensors |
US11382539B2 (en) | 2006-10-04 | 2022-07-12 | Dexcom, Inc. | Analyte sensor |
US11432772B2 (en) | 2006-08-02 | 2022-09-06 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US11559260B2 (en) | 2003-08-22 | 2023-01-24 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US11730407B2 (en) | 2008-03-28 | 2023-08-22 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US11793936B2 (en) | 2009-05-29 | 2023-10-24 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
US11950936B2 (en) | 2023-02-22 | 2024-04-09 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4823443B2 (en) * | 2000-07-14 | 2011-11-24 | 日機装株式会社 | Implantable artificial pancreas device |
SI1972275T1 (en) * | 2007-03-20 | 2016-02-29 | F. Hoffmann-La Roche Ag | System for in vivo measurement of an analyte concentration |
KR101088864B1 (en) | 2010-12-10 | 2011-12-06 | (주)에이치시티 | Nano-paticles exposure chamber for in-vivo and in-vitro type testing toxicity of nano-paticles |
US10509008B2 (en) * | 2015-04-29 | 2019-12-17 | Taiwan Semiconductor Manufacturing Co., Ltd. | Biological device and biosensing method thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990005910A1 (en) * | 1988-11-14 | 1990-05-31 | I Stat Corp | Wholly microfabricated biosensors and process for the manufacture and use thereof |
US5109850A (en) * | 1990-02-09 | 1992-05-05 | Massachusetts Institute Of Technology | Automatic blood monitoring for medication delivery method and apparatus |
US5294541A (en) * | 1989-09-21 | 1994-03-15 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Real-time monitoring of oxidative products from in vitro cell-biomaterial interaction using chemiluminescence |
US5756351A (en) * | 1997-01-13 | 1998-05-26 | The Regents Of The University Of California | Biomolecular optical sensors |
WO1998022820A1 (en) * | 1996-11-21 | 1998-05-28 | Lawrence Livermore National Laboratory | Detection of biological molecules using boronate-based chemical amplification and optical sensors |
-
1999
- 1999-12-02 EP EP99964095A patent/EP1135677A1/en not_active Withdrawn
- 1999-12-02 WO PCT/US1999/028733 patent/WO2000033065A1/en not_active Application Discontinuation
- 1999-12-02 JP JP2000585651A patent/JP2002531194A/en not_active Ceased
- 1999-12-02 CA CA002352571A patent/CA2352571C/en not_active Expired - Fee Related
- 1999-12-02 KR KR1020017006949A patent/KR20010102951A/en not_active Application Discontinuation
- 1999-12-02 AU AU20408/00A patent/AU762948B2/en not_active Ceased
-
2002
- 2002-03-20 HK HK02102125.2A patent/HK1040767A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990005910A1 (en) * | 1988-11-14 | 1990-05-31 | I Stat Corp | Wholly microfabricated biosensors and process for the manufacture and use thereof |
US5294541A (en) * | 1989-09-21 | 1994-03-15 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Real-time monitoring of oxidative products from in vitro cell-biomaterial interaction using chemiluminescence |
US5109850A (en) * | 1990-02-09 | 1992-05-05 | Massachusetts Institute Of Technology | Automatic blood monitoring for medication delivery method and apparatus |
WO1998022820A1 (en) * | 1996-11-21 | 1998-05-28 | Lawrence Livermore National Laboratory | Detection of biological molecules using boronate-based chemical amplification and optical sensors |
US5756351A (en) * | 1997-01-13 | 1998-05-26 | The Regents Of The University Of California | Biomolecular optical sensors |
Cited By (298)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9439589B2 (en) | 1997-03-04 | 2016-09-13 | Dexcom, Inc. | Device and method for determining analyte levels |
US8923947B2 (en) | 1997-03-04 | 2014-12-30 | Dexcom, Inc. | Device and method for determining analyte levels |
US6558321B1 (en) | 1997-03-04 | 2003-05-06 | Dexcom, Inc. | Systems and methods for remote monitoring and modulation of medical devices |
US9931067B2 (en) | 1997-03-04 | 2018-04-03 | Dexcom, Inc. | Device and method for determining analyte levels |
US9339223B2 (en) | 1997-03-04 | 2016-05-17 | Dexcom, Inc. | Device and method for determining analyte levels |
US9155496B2 (en) | 1997-03-04 | 2015-10-13 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US10478108B2 (en) | 1998-04-30 | 2019-11-19 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8880137B2 (en) | 1998-04-30 | 2014-11-04 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8840553B2 (en) | 1998-04-30 | 2014-09-23 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9072477B2 (en) | 1998-04-30 | 2015-07-07 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9011331B2 (en) | 1998-04-30 | 2015-04-21 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066697B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9042953B2 (en) | 1998-04-30 | 2015-05-26 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9326714B2 (en) | 1998-04-30 | 2016-05-03 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066694B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9014773B2 (en) | 1998-04-30 | 2015-04-21 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
WO2002013686A1 (en) * | 2000-08-11 | 2002-02-21 | Dexcom Inc. | Systems and methods for remote monitoring and modulation of medical devices |
WO2002014551A3 (en) * | 2000-08-14 | 2003-03-20 | Univ Tennessee Res Corp | Bioluminescent methods for direct visual detection of environmental compounds |
WO2002014551A2 (en) * | 2000-08-14 | 2002-02-21 | The University Of Tennessee Research Corporation | Bioluminescent methods for direct visual detection of environmental compounds |
WO2002027294A3 (en) * | 2000-09-29 | 2002-12-05 | Michele Delsanter | Multifunctional and multiparametric biochip arrangement |
WO2002027294A2 (en) * | 2000-09-29 | 2002-04-04 | Michele Delsanter | Multifunctional and multiparametric biochip arrangement |
WO2002039112A3 (en) * | 2000-11-09 | 2003-02-06 | Sicel Technologies Inc | In vivo detection of biomolecule concentrations using fluorescent tags |
WO2002039112A2 (en) * | 2000-11-09 | 2002-05-16 | Sicel Technologies, Inc. | In vivo detection of biomolecule concentrations using fluorescent tags |
US9498159B2 (en) | 2001-01-02 | 2016-11-22 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9011332B2 (en) | 2001-01-02 | 2015-04-21 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9610034B2 (en) | 2001-01-02 | 2017-04-04 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9477811B2 (en) | 2001-04-02 | 2016-10-25 | Abbott Diabetes Care Inc. | Blood glucose tracking apparatus and methods |
US7653424B2 (en) | 2001-04-27 | 2010-01-26 | Eyesense Ag | Apparatus for measuring blood glucose concentrations |
WO2002087429A1 (en) * | 2001-04-27 | 2002-11-07 | Novartis Ag | Apparatus for measuring blood glucose concentrations |
US8840552B2 (en) | 2001-07-27 | 2014-09-23 | Dexcom, Inc. | Membrane for use with implantable devices |
US10039480B2 (en) | 2001-07-27 | 2018-08-07 | Dexcom, Inc. | Membrane for use with implantable devices |
US9804114B2 (en) | 2001-07-27 | 2017-10-31 | Dexcom, Inc. | Sensor head for use with implantable devices |
US9328371B2 (en) | 2001-07-27 | 2016-05-03 | Dexcom, Inc. | Sensor head for use with implantable devices |
US9532741B2 (en) | 2001-07-27 | 2017-01-03 | Dexcom, Inc. | Membrane for use with implantable devices |
JP2005525139A (en) * | 2001-10-23 | 2005-08-25 | メドトロニック ミニメド インコーポレイテッド | Method and system for non-vascular sensor implantation |
WO2003051191A1 (en) * | 2001-12-17 | 2003-06-26 | Danfoss A/S | Method and device for monitoring analyte concentration by optical detection |
US7248906B2 (en) | 2001-12-17 | 2007-07-24 | Danfoss A/S | Method and device for monitoring analyte concentration by optical detection |
US9282925B2 (en) | 2002-02-12 | 2016-03-15 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9549693B2 (en) | 2002-05-22 | 2017-01-24 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US11020026B2 (en) | 2002-05-22 | 2021-06-01 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US8865249B2 (en) | 2002-05-22 | 2014-10-21 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US10052051B2 (en) | 2002-05-22 | 2018-08-21 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US10154807B2 (en) | 2002-05-22 | 2018-12-18 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US9179869B2 (en) | 2002-05-22 | 2015-11-10 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US9801574B2 (en) | 2002-05-22 | 2017-10-31 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US7736309B2 (en) | 2002-09-27 | 2010-06-15 | Medtronic Minimed, Inc. | Implantable sensor method and system |
JP2006500170A (en) * | 2002-09-27 | 2006-01-05 | メドトロニック ミニメド インコーポレイテッド | Implantable sensor method and system |
US10039881B2 (en) | 2002-12-31 | 2018-08-07 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
US7778695B2 (en) | 2003-02-19 | 2010-08-17 | Sicel Technologies, Inc. | In vivo fluorescence sensors, systems, and related methods operating in conjunction with fluorescent analytes |
US9730584B2 (en) | 2003-06-10 | 2017-08-15 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
US9763609B2 (en) | 2003-07-25 | 2017-09-19 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US10376143B2 (en) | 2003-07-25 | 2019-08-13 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US8845536B2 (en) | 2003-08-01 | 2014-09-30 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8915849B2 (en) | 2003-08-01 | 2014-12-23 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8886273B2 (en) | 2003-08-01 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US9895089B2 (en) | 2003-08-01 | 2018-02-20 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US10786185B2 (en) | 2003-08-01 | 2020-09-29 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8986209B2 (en) | 2003-08-01 | 2015-03-24 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9585607B2 (en) | 2003-08-22 | 2017-03-07 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8843187B2 (en) | 2003-08-22 | 2014-09-23 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9149219B2 (en) | 2003-08-22 | 2015-10-06 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9510782B2 (en) | 2003-08-22 | 2016-12-06 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US11589823B2 (en) | 2003-08-22 | 2023-02-28 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US11559260B2 (en) | 2003-08-22 | 2023-01-24 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
US9750460B2 (en) | 2003-08-22 | 2017-09-05 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9420968B2 (en) | 2003-08-22 | 2016-08-23 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9427183B2 (en) | 2003-08-22 | 2016-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9724045B1 (en) | 2003-08-22 | 2017-08-08 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9247901B2 (en) | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9649069B2 (en) | 2003-08-22 | 2017-05-16 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9538946B2 (en) | 2003-11-19 | 2017-01-10 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
US11564602B2 (en) | 2003-11-19 | 2023-01-31 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
US9579053B2 (en) | 2003-12-05 | 2017-02-28 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
USRE44695E1 (en) | 2003-12-05 | 2014-01-07 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US10299712B2 (en) | 2003-12-05 | 2019-05-28 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
USRE43039E1 (en) | 2003-12-05 | 2011-12-20 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US10188333B2 (en) | 2003-12-05 | 2019-01-29 | Dexcom, Inc. | Calibration techniques for a continuous analyte sensor |
US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8929968B2 (en) | 2003-12-05 | 2015-01-06 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US11020031B1 (en) | 2003-12-05 | 2021-06-01 | Dexcom, Inc. | Analyte sensor |
US8911369B2 (en) | 2003-12-05 | 2014-12-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US11000215B1 (en) | 2003-12-05 | 2021-05-11 | Dexcom, Inc. | Analyte sensor |
US9420965B2 (en) | 2003-12-09 | 2016-08-23 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US9351668B2 (en) | 2003-12-09 | 2016-05-31 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US10898113B2 (en) | 2003-12-09 | 2021-01-26 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US9107623B2 (en) | 2003-12-09 | 2015-08-18 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US9750441B2 (en) | 2003-12-09 | 2017-09-05 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US9498155B2 (en) | 2003-12-09 | 2016-11-22 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US11638541B2 (en) | 2003-12-09 | 2023-05-02 | Dexconi, Inc. | Signal processing for continuous analyte sensor |
US9192328B2 (en) | 2003-12-09 | 2015-11-24 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US9364173B2 (en) | 2003-12-09 | 2016-06-14 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US8751003B2 (en) | 2004-02-11 | 2014-06-10 | Ethicon, Inc. | Conductive mesh for neurostimulation |
US8165695B2 (en) | 2004-02-11 | 2012-04-24 | Ethicon, Inc. | System and method for selectively stimulating different body parts |
US7979137B2 (en) | 2004-02-11 | 2011-07-12 | Ethicon, Inc. | System and method for nerve stimulation |
US7647112B2 (en) | 2004-02-11 | 2010-01-12 | Ethicon, Inc. | System and method for selectively stimulating different body parts |
US8926585B2 (en) | 2004-02-26 | 2015-01-06 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US10278580B2 (en) | 2004-02-26 | 2019-05-07 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US11246990B2 (en) | 2004-02-26 | 2022-02-15 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US10966609B2 (en) | 2004-02-26 | 2021-04-06 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US9937293B2 (en) | 2004-02-26 | 2018-04-10 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US10835672B2 (en) | 2004-02-26 | 2020-11-17 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US9833143B2 (en) | 2004-05-03 | 2017-12-05 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10327638B2 (en) | 2004-05-03 | 2019-06-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10918314B2 (en) | 2004-07-13 | 2021-02-16 | Dexcom, Inc. | Analyte sensor |
US9060742B2 (en) | 2004-07-13 | 2015-06-23 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10314525B2 (en) | 2004-07-13 | 2019-06-11 | Dexcom, Inc. | Analyte sensor |
US10709363B2 (en) | 2004-07-13 | 2020-07-14 | Dexcom, Inc. | Analyte sensor |
US8690775B2 (en) | 2004-07-13 | 2014-04-08 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8858434B2 (en) | 2004-07-13 | 2014-10-14 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8886272B2 (en) | 2004-07-13 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US9044199B2 (en) | 2004-07-13 | 2015-06-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9055901B2 (en) | 2004-07-13 | 2015-06-16 | Dexcom, Inc. | Transcutaneous analyte sensor |
US11883164B2 (en) | 2004-07-13 | 2024-01-30 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10709362B2 (en) | 2004-07-13 | 2020-07-14 | Dexcom, Inc. | Analyte sensor |
US10722152B2 (en) | 2004-07-13 | 2020-07-28 | Dexcom, Inc. | Analyte sensor |
US9078626B2 (en) | 2004-07-13 | 2015-07-14 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10799159B2 (en) | 2004-07-13 | 2020-10-13 | Dexcom, Inc. | Analyte sensor |
US10022078B2 (en) | 2004-07-13 | 2018-07-17 | Dexcom, Inc. | Analyte sensor |
US10799158B2 (en) | 2004-07-13 | 2020-10-13 | Dexcom, Inc. | Analyte sensor |
US11064917B2 (en) | 2004-07-13 | 2021-07-20 | Dexcom, Inc. | Analyte sensor |
US10813576B2 (en) | 2004-07-13 | 2020-10-27 | Dexcom, Inc. | Analyte sensor |
US9610031B2 (en) | 2004-07-13 | 2017-04-04 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10827956B2 (en) | 2004-07-13 | 2020-11-10 | Dexcom, Inc. | Analyte sensor |
US11045120B2 (en) | 2004-07-13 | 2021-06-29 | Dexcom, Inc. | Analyte sensor |
US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
US9833176B2 (en) | 2004-07-13 | 2017-12-05 | Dexcom, Inc. | Transcutaneous analyte sensor |
US11026605B1 (en) | 2004-07-13 | 2021-06-08 | Dexcom, Inc. | Analyte sensor |
US9668677B2 (en) | 2004-07-13 | 2017-06-06 | Dexcom, Inc. | Analyte sensor |
US9814414B2 (en) | 2004-07-13 | 2017-11-14 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9414777B2 (en) | 2004-07-13 | 2016-08-16 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10524703B2 (en) | 2004-07-13 | 2020-01-07 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10918315B2 (en) | 2004-07-13 | 2021-02-16 | Dexcom, Inc. | Analyte sensor |
US9801572B2 (en) | 2004-07-13 | 2017-10-31 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10993642B2 (en) | 2004-07-13 | 2021-05-04 | Dexcom, Inc. | Analyte sensor |
US10993641B2 (en) | 2004-07-13 | 2021-05-04 | Dexcom, Inc. | Analyte sensor |
US10980452B2 (en) | 2004-07-13 | 2021-04-20 | Dexcom, Inc. | Analyte sensor |
US10918313B2 (en) | 2004-07-13 | 2021-02-16 | Dexcom, Inc. | Analyte sensor |
US10932700B2 (en) | 2004-07-13 | 2021-03-02 | Dexcom, Inc. | Analyte sensor |
US9775543B2 (en) | 2004-07-13 | 2017-10-03 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10610102B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10856787B2 (en) | 2005-03-10 | 2020-12-08 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10617336B2 (en) | 2005-03-10 | 2020-04-14 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10925524B2 (en) | 2005-03-10 | 2021-02-23 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10743801B2 (en) | 2005-03-10 | 2020-08-18 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610136B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US11051726B2 (en) | 2005-03-10 | 2021-07-06 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US9220449B2 (en) | 2005-03-10 | 2015-12-29 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US11000213B2 (en) | 2005-03-10 | 2021-05-11 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610137B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10918318B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10918316B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610135B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10898114B2 (en) | 2005-03-10 | 2021-01-26 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US9918668B2 (en) | 2005-03-10 | 2018-03-20 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10709364B2 (en) | 2005-03-10 | 2020-07-14 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US9078608B2 (en) | 2005-03-10 | 2015-07-14 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10918317B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10624539B2 (en) | 2005-03-10 | 2020-04-21 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9314196B2 (en) | 2005-03-10 | 2016-04-19 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10716498B2 (en) | 2005-03-10 | 2020-07-21 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10376188B2 (en) | 2005-04-15 | 2019-08-13 | Dexcom, Inc. | Analyte sensing biointerface |
US10667729B2 (en) | 2005-04-15 | 2020-06-02 | Dexcom, Inc. | Analyte sensing biointerface |
US10667730B2 (en) | 2005-04-15 | 2020-06-02 | Dexcom, Inc. | Analyte sensing biointerface |
US10702193B2 (en) | 2005-04-15 | 2020-07-07 | Dexcom, Inc. | Analyte sensing biointerface |
US9788766B2 (en) | 2005-04-15 | 2017-10-17 | Dexcom, Inc. | Analyte sensing biointerface |
US10300507B2 (en) | 2005-05-05 | 2019-05-28 | Dexcom, Inc. | Cellulosic-based resistance domain for an analyte sensor |
DE102005027245A1 (en) * | 2005-06-13 | 2006-12-21 | Siemens Ag | CMOS (complementary metal oxide semiconductor) circuit arrangement has operating circuit region with decoder to address at least one of sensor and actuator elements, and evaluation and driver circuits for sensor and actuator elements |
US10813577B2 (en) | 2005-06-21 | 2020-10-27 | Dexcom, Inc. | Analyte sensor |
US10610103B2 (en) | 2005-06-21 | 2020-04-07 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10709332B2 (en) | 2005-06-21 | 2020-07-14 | Dexcom, Inc. | Transcutaneous analyte sensor |
US11363975B2 (en) | 2005-11-01 | 2022-06-21 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US10952652B2 (en) | 2005-11-01 | 2021-03-23 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US10201301B2 (en) | 2005-11-01 | 2019-02-12 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US10231654B2 (en) | 2005-11-01 | 2019-03-19 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8920319B2 (en) | 2005-11-01 | 2014-12-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9326716B2 (en) | 2005-11-01 | 2016-05-03 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US11272867B2 (en) | 2005-11-01 | 2022-03-15 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8915850B2 (en) | 2005-11-01 | 2014-12-23 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US11399748B2 (en) | 2005-11-01 | 2022-08-02 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US11911151B1 (en) | 2005-11-01 | 2024-02-27 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US11103165B2 (en) | 2005-11-01 | 2021-08-31 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9078607B2 (en) | 2005-11-01 | 2015-07-14 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9323898B2 (en) | 2005-11-04 | 2016-04-26 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
US11538580B2 (en) | 2005-11-04 | 2022-12-27 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
US9669162B2 (en) | 2005-11-04 | 2017-06-06 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
US9757061B2 (en) | 2006-01-17 | 2017-09-12 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US11191458B2 (en) | 2006-01-17 | 2021-12-07 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US11596332B2 (en) | 2006-01-17 | 2023-03-07 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US10265000B2 (en) | 2006-01-17 | 2019-04-23 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US8968198B2 (en) | 2006-02-22 | 2015-03-03 | Dexcom, Inc. | Analyte sensor |
US9724028B2 (en) | 2006-02-22 | 2017-08-08 | Dexcom, Inc. | Analyte sensor |
US8933664B2 (en) | 2006-03-31 | 2015-01-13 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
US9380971B2 (en) | 2006-03-31 | 2016-07-05 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
US9743863B2 (en) | 2006-03-31 | 2017-08-29 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
US9625413B2 (en) | 2006-03-31 | 2017-04-18 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
US9039975B2 (en) | 2006-03-31 | 2015-05-26 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
US11432772B2 (en) | 2006-08-02 | 2022-09-06 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US11382539B2 (en) | 2006-10-04 | 2022-07-12 | Dexcom, Inc. | Analyte sensor |
US9504413B2 (en) | 2006-10-04 | 2016-11-29 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US9451908B2 (en) | 2006-10-04 | 2016-09-27 | Dexcom, Inc. | Analyte sensor |
US10136844B2 (en) | 2006-10-04 | 2018-11-27 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US10349873B2 (en) | 2006-10-04 | 2019-07-16 | Dexcom, Inc. | Analyte sensor |
US11399745B2 (en) | 2006-10-04 | 2022-08-02 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8930203B2 (en) | 2007-02-18 | 2015-01-06 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
US9095290B2 (en) | 2007-03-01 | 2015-08-04 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
US9801545B2 (en) | 2007-03-01 | 2017-10-31 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
US9574914B2 (en) | 2007-05-08 | 2017-02-21 | Abbott Diabetes Care Inc. | Method and device for determining elapsed sensor life |
US9177456B2 (en) | 2007-05-08 | 2015-11-03 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US11696684B2 (en) | 2007-05-08 | 2023-07-11 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US10653317B2 (en) | 2007-05-08 | 2020-05-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US10178954B2 (en) | 2007-05-08 | 2019-01-15 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US9649057B2 (en) | 2007-05-08 | 2017-05-16 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US9035767B2 (en) | 2007-05-08 | 2015-05-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US9949678B2 (en) | 2007-05-08 | 2018-04-24 | Abbott Diabetes Care Inc. | Method and device for determining elapsed sensor life |
US9314198B2 (en) | 2007-05-08 | 2016-04-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US9000929B2 (en) | 2007-05-08 | 2015-04-07 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US10952611B2 (en) | 2007-05-08 | 2021-03-23 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US10791928B2 (en) | 2007-05-18 | 2020-10-06 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US10403012B2 (en) | 2007-06-08 | 2019-09-03 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US9741139B2 (en) | 2007-06-08 | 2017-08-22 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US11373347B2 (en) | 2007-06-08 | 2022-06-28 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US9451910B2 (en) | 2007-09-13 | 2016-09-27 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9668682B2 (en) | 2007-09-13 | 2017-06-06 | Dexcom, Inc. | Transcutaneous analyte sensor |
US11672422B2 (en) | 2007-09-13 | 2023-06-13 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10653835B2 (en) | 2007-10-09 | 2020-05-19 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US11744943B2 (en) | 2007-10-09 | 2023-09-05 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US11160926B1 (en) | 2007-10-09 | 2021-11-02 | Dexcom, Inc. | Pre-connected analyte sensors |
US9717449B2 (en) | 2007-10-25 | 2017-08-01 | Dexcom, Inc. | Systems and methods for processing sensor data |
US10182751B2 (en) | 2007-10-25 | 2019-01-22 | Dexcom, Inc. | Systems and methods for processing sensor data |
US11272869B2 (en) | 2007-10-25 | 2022-03-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9135402B2 (en) | 2007-12-17 | 2015-09-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
US10506982B2 (en) | 2007-12-17 | 2019-12-17 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9839395B2 (en) | 2007-12-17 | 2017-12-12 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9339238B2 (en) | 2007-12-17 | 2016-05-17 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9149233B2 (en) | 2007-12-17 | 2015-10-06 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9901307B2 (en) | 2007-12-17 | 2018-02-27 | Dexcom, Inc. | Systems and methods for processing sensor data |
US10827980B2 (en) | 2007-12-17 | 2020-11-10 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9149234B2 (en) | 2007-12-17 | 2015-10-06 | Dexcom, Inc. | Systems and methods for processing sensor data |
US11342058B2 (en) | 2007-12-17 | 2022-05-24 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9020572B2 (en) | 2008-02-21 | 2015-04-28 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
US9143569B2 (en) | 2008-02-21 | 2015-09-22 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
US11102306B2 (en) | 2008-02-21 | 2021-08-24 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
US10602968B2 (en) | 2008-03-25 | 2020-03-31 | Dexcom, Inc. | Analyte sensor |
US11896374B2 (en) | 2008-03-25 | 2024-02-13 | Dexcom, Inc. | Analyte sensor |
US11730407B2 (en) | 2008-03-28 | 2023-08-22 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US9173607B2 (en) | 2008-03-28 | 2015-11-03 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US10143410B2 (en) | 2008-03-28 | 2018-12-04 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US9693721B2 (en) | 2008-03-28 | 2017-07-04 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US9173606B2 (en) | 2008-03-28 | 2015-11-03 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US9572523B2 (en) | 2008-03-28 | 2017-02-21 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US9549699B2 (en) | 2008-03-28 | 2017-01-24 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US9566026B2 (en) | 2008-03-28 | 2017-02-14 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US11147483B2 (en) | 2008-03-28 | 2021-10-19 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US8954128B2 (en) | 2008-03-28 | 2015-02-10 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US11918354B2 (en) | 2008-09-19 | 2024-03-05 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US10028683B2 (en) | 2008-09-19 | 2018-07-24 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US10028684B2 (en) | 2008-09-19 | 2018-07-24 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US10561352B2 (en) | 2008-09-19 | 2020-02-18 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US9339222B2 (en) | 2008-09-19 | 2016-05-17 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US10980461B2 (en) | 2008-11-07 | 2021-04-20 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US9066709B2 (en) | 2009-01-29 | 2015-06-30 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
US10537678B2 (en) | 2009-03-27 | 2020-01-21 | Dexcom, Inc. | Methods and systems for promoting glucose management |
US10610642B2 (en) | 2009-03-27 | 2020-04-07 | Dexcom, Inc. | Methods and systems for promoting glucose management |
US9446194B2 (en) | 2009-03-27 | 2016-09-20 | Dexcom, Inc. | Methods and systems for promoting glucose management |
US10675405B2 (en) | 2009-03-27 | 2020-06-09 | Dexcom, Inc. | Methods and systems for simulating glucose response to simulated actions |
US9226701B2 (en) | 2009-04-28 | 2016-01-05 | Abbott Diabetes Care Inc. | Error detection in critical repeating data in a wireless sensor system |
US11872370B2 (en) | 2009-05-29 | 2024-01-16 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
US11793936B2 (en) | 2009-05-29 | 2023-10-24 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
US9907497B2 (en) | 2009-07-02 | 2018-03-06 | Dexcom, Inc. | Analyte sensor |
US9320466B2 (en) | 2009-07-02 | 2016-04-26 | Dexcom, Inc. | Analyte sensor |
US11559229B2 (en) | 2009-07-02 | 2023-01-24 | Dexcom, Inc. | Analyte sensor |
US10420494B2 (en) | 2009-07-02 | 2019-09-24 | Dexcom, Inc. | Analyte sensor |
US9968302B2 (en) | 2009-08-31 | 2018-05-15 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
US11045147B2 (en) | 2009-08-31 | 2021-06-29 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
US8993331B2 (en) | 2009-08-31 | 2015-03-31 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods for managing power and noise |
US10429250B2 (en) | 2009-08-31 | 2019-10-01 | Abbott Diabetes Care, Inc. | Analyte monitoring system and methods for managing power and noise |
US11635332B2 (en) | 2009-08-31 | 2023-04-25 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods for managing power and noise |
US11150145B2 (en) | 2009-08-31 | 2021-10-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods for managing power and noise |
US9314195B2 (en) | 2009-08-31 | 2016-04-19 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
US10349874B2 (en) | 2009-09-29 | 2019-07-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
US9320461B2 (en) | 2009-09-29 | 2016-04-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
US9750439B2 (en) | 2009-09-29 | 2017-09-05 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
JP2013517029A (en) * | 2010-01-13 | 2013-05-16 | ユニヴェルシテ ド ボルドー アン | Sensor for measuring activity of pancreatic β cells or islets of Langerhans, manufacture and use of such sensor |
US9980669B2 (en) | 2011-11-07 | 2018-05-29 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods |
US11612363B2 (en) | 2012-09-17 | 2023-03-28 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
US9968306B2 (en) | 2012-09-17 | 2018-05-15 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
US11706876B2 (en) | 2017-10-24 | 2023-07-18 | Dexcom, Inc. | Pre-connected analyte sensors |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
US11350862B2 (en) | 2017-10-24 | 2022-06-07 | Dexcom, Inc. | Pre-connected analyte sensors |
US11382540B2 (en) | 2017-10-24 | 2022-07-12 | Dexcom, Inc. | Pre-connected analyte sensors |
US11943876B2 (en) | 2017-10-24 | 2024-03-26 | Dexcom, Inc. | Pre-connected analyte sensors |
CN110940714B (en) * | 2018-09-21 | 2023-09-15 | 罗斯蒙特公司 | Analyzing predicted lifetime of a sensor |
CN110940714A (en) * | 2018-09-21 | 2020-03-31 | 罗斯蒙特公司 | Analyzing predicted lifetime of a sensor |
WO2021030416A1 (en) * | 2019-08-12 | 2021-02-18 | Efferent Labs, Inc. | Wearable devices for monitoring physiological changes and methods of use |
US20210045660A1 (en) * | 2019-08-12 | 2021-02-18 | Efferent Labs, Inc. | Wearable devices for monitoring physiological changes and methods of use |
US11950936B2 (en) | 2023-02-22 | 2024-04-09 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
Also Published As
Publication number | Publication date |
---|---|
EP1135677A1 (en) | 2001-09-26 |
HK1040767A1 (en) | 2002-06-21 |
AU2040800A (en) | 2000-06-19 |
CA2352571C (en) | 2007-02-27 |
KR20010102951A (en) | 2001-11-17 |
JP2002531194A (en) | 2002-09-24 |
CA2352571A1 (en) | 2000-06-08 |
AU762948B2 (en) | 2003-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6673596B1 (en) | In vivo biosensor apparatus and method of use | |
AU762948B2 (en) | In vivo biosensor apparatus and method of use | |
US6514689B2 (en) | Hydrogel biosensor | |
Wilkins et al. | Integrated implantable device for long-term glucose monitoring | |
EP1786834B1 (en) | Implantable power sources and sensors | |
US20010041830A1 (en) | Apparatus for measurment and control of the content of glucose, lactate or other metabolites in biological fluids | |
CA2545715C (en) | Long term analyte sensor array | |
US5476776A (en) | Immobilized enzymes for use in an electrochemical sensor | |
EP1751302B1 (en) | Analyte sensors and methods for making and using them | |
Bobrowski et al. | Long-term implantable glucose biosensors | |
CN103917154B (en) | Orthogonal redundancy sensing system and method | |
US6702857B2 (en) | Membrane for use with implantable devices | |
US6512939B1 (en) | Implantable enzyme-based monitoring systems adapted for long term use | |
US4545382A (en) | Sensor for components of a liquid mixture | |
KR100771711B1 (en) | Glucose biosensor | |
US20140094746A1 (en) | Fluid Delivery System With Electrochemical Sensing Of Analyte Concentration Levels | |
US20140135605A1 (en) | Methods and systems for optimizing sensor function by the application of voltage | |
Logeart-Avramoglou et al. | In vitro and in vivo bioluminescent quantification of viable stem cells in engineered constructs | |
CN103328650A (en) | Layered enzyme compositions for use with analyte sensors | |
US20160324449A1 (en) | Implantable sensors | |
CN109312383A (en) | In-situ chemical storehouse for continuous glucose sensor | |
CN102439164A (en) | Enzyme stabilization in electrochemical sensors | |
JP2009117321A (en) | Microbial electrode, and fuel cell and sensor using this | |
Abel et al. | Stability of immobilized enzymes as biosensors for continuous application in vitro and in vivo | |
CN101266242A (en) | Probe and method for detecting membrane of glucose transporter 4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2352571 Country of ref document: CA Ref country code: CA Ref document number: 2352571 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20408/00 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 585651 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017006949 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999964095 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999964095 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017006949 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 20408/00 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020017006949 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999964095 Country of ref document: EP |